UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA
FEDERAL TRADE COMMISSION,
Plaintiff,
Civil Action No. 19-2337 (TJK)
v.
RAG-STIFTUNG et al.,
Defendants.
MEMORANDUM OPINION
Hydrogen peroxide (H2O2) is a veritable swiss army knife of chemicals. Often an
environmentally friendly alternative to other substances, it bleaches paper, treats wastewater,
disinfects knee scrapes, fuels rockets, and plays a role in manufacturing semiconductors, to name
a few of its myriad applications. In November 2018, two of the five North American suppliers
of hydrogen peroxide, Evonik and PeroxyChem, announced a proposed $625 million merger,
and not long after, the Federal Trade Commission (FTC) launched an investigation into the
potential anticompetitive effect of the merger. After a nine-month investigation, the FTC filed
both an administrative complaint and this preliminary injunction action under Section 13(b) of
the Federal Trade Commission Act, 15 U.S.C. § 53(b), and Section 7 of the Clayton Act, 15
U.S.C. § 18. The Court held a two-week evidentiary hearing in November 2019, during which it
heard from twenty fact witnesses and two experts and received hundreds of exhibits.
The FTC seeks a preliminary injunction barring Evonik’s acquisition of PeroxyChem,
and it has the burden of showing that it is likely the proposed merger will substantially lessen
competition in a relevant market. But the FTC made an important misstep. Rather than
recognizing how hydrogen peroxide suppliers compete for customers served by its countless end
uses—accounting for products’ variations in purity, concentration, stabilizer chemicals,
profitability, and even regulatory approval—the FTC pleaded and argued for a single market for
all “non-electronics” hydrogen peroxide. And because evaluating a merger’s competitive effects
on a market requires the FTC to properly define a market in terms of both product and
geography, that oversimplification all but precludes the Court from siding with it. For the
reasons explained below, the Court concludes that the FTC has not made out its prima facie case,
which requires it to show undue concentration for a particular product in a particular geographic
area, and it has not otherwise shown a likelihood that the proposed Evonik-PeroxyChem merger
will substantially harm competition. The Court must therefore deny the FTC’s motion for a
preliminary injunction, ECF No. 3.1
Background
A. Hydrogen Peroxide Suppliers
There are five suppliers of hydrogen peroxide in North America: Evonik, PeroxyChem,
Solvay, Arkema, and Nouryon. DPFFCL at 13 ¶ 34. Evonik is an international chemical
company based in Germany and controlled by Defendant RAG-Stiftung. Id. at 5 ¶ 3. Evonik
produces hydrogen peroxide at three North American plants located in Mobile, Alabama;
Gibbons, Alberta; and Maitland, Ontario. PPFFCL at 1 ¶ 1. Evonik seeks to acquire
PeroxyChem, a Philadelphia-based international manufacturer of hydrogen peroxide, persulfates,
and peracetic acid. DPFFCL at 5 ¶ 5. PeroxyChem produces hydrogen peroxide at two North
1
The documents submitted to the Court in this matter include: Complaint, ECF No. 1
(“Compl.”); Plaintiff’s Memorandum in Support of Motion for Preliminary Injunction, ECF No.
45-1 (“Br.”); Defendants’ Opposition to Plaintiff’s Memorandum, ECF No. 56-1 (“Opp.”);
Plaintiff’s Proposed Findings of Fact and Conclusions of Law, ECF No. 137-1 (“PPFFCL”);
Defendants’ Proposed Findings of Fact and Conclusions of Law, ECF No. 138-1 (“DPFFCL”).
The Court hereby incorporates the FTC’s Glossary of Hearing Witnesses, Deponents, and
Declarants, PPFFCL at x–xi.
2
American plants in Bayport, Texas, and Prince George, British Columbia. PPFFCL at 1–2 ¶ 2.
Solvay has one plant in Deer Park, Texas—fewer than ten miles from PeroxyChem’s Bayport
plant—and one plant in Longview, Washington; Arkema has one plant in Memphis, Tennessee,
and one in Becancour, Quebec; and Nouryon has a plant in Columbus, Mississippi. DPFFCL at
13–14 ¶ 35.
B. The Manufacture of Hydrogen Peroxide Products
To manufacture hydrogen peroxide, suppliers move a working solution through a
hydrogenation, oxidation, and extraction process, continuously and nearly 365 days a year.
PPFFCL at 4 ¶ 12; DPFFCL at 8 ¶ 16. The process produces “crude” hydrogen peroxide.
PPFFCL at 4 ¶ 12. Suppliers stabilize the crude with chemical additives to prevent the product
from decomposing and concentrate or distill it to produce a marketable product known as
“standard grade” hydrogen peroxide, which is the lowest purity sold. Id.; DPFFCL at 9 ¶¶ 18–
20. Suppliers formulate standard grade hydrogen peroxide at different concentration levels and
add stabilizers to serve a variety of end uses, like bleaching pulp and paper (the largest hydrogen
peroxide end use) and textiles; it is also used in wastewater treatment and in the mining and oil
and gas industries. PPFFCL at 4 ¶ 13; Dumas Hrg. Tr. 235:1–3; Suter Hrg. Tr. 408:8–14;
Costanzo Hrg. Tr. 1223:6–13; Montag Hrg. Tr. 1566:5–1567:2, 1600:23–1601:3. Stabilizer
packages are proprietary, and a stabilizer like tin that works well for some applications does not
for others. DPFFCL at 7–8 ¶ 13; Corson Hrg. Tr. 666:6–667:16; DX0348; PX1522-001 to -002;
PX1055-001.
Suppliers can also purify standard grade to make “specialty grade” hydrogen peroxide.
PPFFCL at 9 ¶ 27; DPFFCL at 9–10 ¶¶ 21–22. This higher grade or purity level also serves a
variety of end uses. For example, in the chemical synthesis space, manufacturers use specialty
grade hydrogen peroxide to make sodium chlorite, organic peroxides, and epoxidized soybean
3
oil; in the home and personal care space, specialty grade is used in products for hair and teeth
bleaching and in contact lens solutions; and in the food packaging space, manufacturers use it as
a disinfectant for aseptic packaging. DPFFCL at 6–7 ¶ 11. These specialty grade applications
not only require specific concentrations and stabilizers, but many of them also require FDA or
EPA approval before purchasers can put them toward their intended uses. See DPFFCL at 8
¶ 14.
A few suppliers further purify specialty grade to produce “pre-electronics grade”
hydrogen peroxide. DPFFCL at 11 ¶ 27. Only Evonik and Arkema sell pre-electronics grade.
Id. Manufacturing this grade of hydrogen peroxide, a product for which suppliers measure
impurities in “parts per billion,” Hamann Hrg. Tr. 1281:13, requires additional equipment,
including a second reverse osmosis unit, more testing (several times a day), specially trained
personnel, a specially equipped room and laboratory, and
. Hamann Hrg. Tr. 1282:3–1286:16. PeroxyChem and Solvay
produce a purified hydrogen peroxide “feedstock” that is a precursor to their production of
electronics grade hydrogen peroxide, but the feedstock is not marketed to customers as pre-
electronics grade hydrogen peroxide. Montag Hrg. Tr. 1528:1–5; Kramer Hrg. Tr. 1635:19–
1636:7; Suter Hrg. Tr. 412:11–17. Over the years,
Hancock Decl. ¶¶ 22–23, JX0001-004; Montag Hrg. Tr. 1531:23–1532:1; Suter Hrg.
Tr. 434:24–435:11; Hill Hrg. Tr. 2080:22–23; JX0001-001; PPFFCL at 10–11 ¶¶ 32–33.
Some suppliers have the capability to refine pre-electronics grade even further to make
the highest purity “electronics grade” hydrogen peroxide. Electronics grade is sold to
4
semiconductor manufacturers to clean and etch silicon microchips. DPFFCL at 11–13 ¶¶ 27, 33.
MGC, PeroxyChem, and Solvay sell electronics grade hydrogen peroxide. Id. at 13 ¶ 33.
As an engineering matter, a plant can only commit 40 to 50 percent of its output to
specialty grade hydrogen peroxide, and only 60 percent of that specialty grade can be purified
into pre-electronics grade, leaving around 36 pounds of pre-electronics grade for every 100
pounds of crude.
; JX0151-015. Suppliers can shift production between different grades of
hydrogen peroxide at a plant merely by adjusting a valve. Hamann Hrg. Tr. 1322:24–1323:13;
see, e.g., Suter Hrg. Tr. 406:6–14 (“We get customer input, we look at historical data, and we
operate with basically a 90-day rolling forecast. We can make any grade at any time of the
month as long as we’re forecasting it properly.” (cleaned up)).
C. The Sale of Hydrogen Peroxide Products
Hydrogen peroxide suppliers sell their products by the pound from around 30 cents per
pound to over a dollar; standard grade is generally the cheapest (and least profitable), then
specialty grade, pre-electronics grade, and electronics grade. DPFFCL at 14 ¶¶ 36–38; JX0066-
43 fig. 10; JX0151-022; . The annual capacity of hydrogen
peroxide plants ranges from around million pounds (Evonik’s Maitland plant) to million
pounds (PeroxyChem’s Bayport plant). PPFFCL at 26–27 ¶¶ 83–93. A significant component
of each product’s price is transportation cost because hydrogen peroxide is typically heavily
diluted with water when it is delivered via railcars and trucks. DPFFCL at 15 ¶ 40. As a result,
the distance between customers and plants is a major factor in competition between suppliers.
Id. ¶ 41.
Hydrogen peroxide suppliers compete for customers across grades and end uses through
blind bidding contests for high-volume, long-term contracts. Id. ¶ 42. A customer publishes a
5
request for proposal (RFP) for a given location, specifying the hydrogen peroxide product,
volume, and contract length sought; suppliers submit confidential bids; and then the customer
usually lets one or more of the bidders know how competitive their bid is (without sharing
specific prices) so that they will lower their bid price. See id. at 15 ¶¶ 42, 44; id. at 66–67 ¶ 173.
This process produces substantial cost savings for hydrogen peroxide customers, and prices have
generally decreased the last few years in part as a result. See DPFFCL at 53–55, 66–67 ¶¶ 143–
46, 173; Hill Rpt., JX0066-097 to -099 figs. 44–46.
D. Procedural History
Evonik announced its intent to acquire PeroxyChem for $625 million in November 2018.
JX0078-011 to -013. The two firms filed a pre-merger notification with the FTC pursuant to the
Hart-Scott-Rodino Improvements Act, 15 U.S.C. § 18a. Compl. ¶ 20. The FTC then launched a
nine-month investigation, during which Defendants produced millions of pages of documents
and the FTC interviewed or deposed more than 50 industry participants. Opp. at 2. The FTC
voted on August 2, 2019, to commence an administrative proceeding to challenge the acquisition
under Section 5 of the Federal Trade Commission Act, 15 U.S.C. § 53(b), and Section 7 of the
Clayton Act, 15 U.S.C. § 18, alleging that the proposed merger will substantially lessen
competition. Compl. ¶ 9. The FTC also filed the instant action and moved for a preliminary
injunction, ECF No. 3, and the parties entered into a stipulated restraining order preventing
Defendants from closing the proposed transaction until five business days after the Court rules
on the motion, ECF No. 9. The parties have delayed the administrative proceeding pending the
Court’s decision. Mahr Hrg. Tr. 2438:3–10.
Within days of the FTC moving for a preliminary injunction in this action, Evonik and
PeroxyChem agreed on a divestiture of PeroxyChem’s plant in Prince George, British Columbia.
Share Purchase Agreement, JX0147-017. If the merger closes, a new competitor, international
6
chemical producer United Initiators GMBH (UI), will purchase the plant for . Id. The
Canadian Competition Bureau investigated the proposed merger with PeroxyChem and the
divestiture of the Prince George plant to UI and entered into a Consent Agreement with Evonik
that approves both. Consent Agreement (Jan. 13, 2020), ECF No. 141-1 at 1–2, 10, 12–13. The
proposed divestiture of the Prince George plant means that the FTC’s challenge to Evonik’s
acquisition of PeroxyChem only concerns its other hydrogen peroxide plant in Bayport, Texas,
setting aside Evonik’s acquisition of PeroxyChem’s unrelated assets for other chemicals. See
DPFFCL at 6 ¶ 7.
Legal Standard
Section 7 of the Clayton Act, 15 U.S.C. § 18, prohibits mergers “where in any line of
commerce or in any activity affecting commerce in any section of the country, the effect of such
acquisition . . . may be substantially to lessen competition, or tend to create a monopoly.”
“Section 7 involves probabilities, not certainties or possibilities,” United States v. Baker Hughes,
Inc., 908 F.2d 981, 984 (D.C. Cir. 1990), and a plaintiff must show that the substantial lessening
of competition will be “sufficiently probable and imminent.” United States v. Marine Bancorp.,
418 U.S. 602, 623 n.22 (1974) (internal quotation omitted); see United States v. Gen. Dynamics
Corp., 415 U.S. 486, 505 (1974).
If the FTC “has reason to believe that a corporation is violating, or is about to violate,
Section 7 of the Clayton Act, the FTC may seek a preliminary injunction” from a federal district
court under Section 13(b) of the Federal Trade Commission Act, 15 U.S.C. § 53(b), “to prevent a
merger pending the Commissioner’s administrative adjudication of the merger’s legality.” FTC
v. H.J. Heinz Co., 246 F.3d 708, 714 (D.C. Cir. 2001) (quoting FTC v. Staples, Inc., 970 F. Supp.
1066, 1070 (D.D.C. 1997) (Staples I)). Section 13(b) provides for a preliminary injunction to
block a merger when “such action would be in the public interest,” after “weighing the equities
7
and considering the Commission’s likelihood of ultimate success.” 15 U.S.C. § 53(b); see Heinz,
246 F.3d at 726.
To obtain a preliminary injunction, the FTC “is not required to prove, nor is the court
required to find, that the proposed merger would in fact violate Section 7 of the Clayton Act.”
Staples I, 970 F. Supp. at 1070. That determination is reserved for the FTC through its
administrative proceeding. Id. However, the FTC must show that there is a “reasonable
probability” or “appreciable danger” that the acquisition may substantially lessen competition.
Id. at 1072; Heinz, 246 F.3d at 713, 719. It can do so by raising “questions going to the merits so
serious, substantial, difficult and doubtful as to make them fair ground for thorough
investigation, study, deliberation and determination by the FTC in the first instance and
ultimately by the Court of Appeals.” Heinz, 246 F.3d at 714–15 (internal citation omitted). That
burden “is not insubstantial, and a showing of a fair or tenable chance of success on the merits
will not suffice for injunctive relief.” FTC v. Arch Coal, Inc., 329 F. Supp. 2d 109, 116 (D.D.C.
2004) (cleaned up); see FTC v. Wilh. Wilhelmsen Holding ASA, 341 F. Supp. 3d 27, 44 (D.D.C.
2018) (“A preliminary injunction in this context remains an extraordinarily drastic remedy,
especially since as a result of the short life-span of most tender offers, the issuance of a
preliminary injunction blocking an acquisition or merger may prevent the transaction from ever
being consummated.” (cleaned up)).
To assess the FTC’s likelihood of success on the merits, the Court applies the D.C.
Circuit’s burden-shifting framework set forth in Baker Hughes, 908 F.2d at 982–83. See Heinz,
246 F.3d at 715. First, the FTC bears the prima facie burden of showing that the Evonik-
PeroxyChem merger will lead to “undue concentration in the market for a particular product in a
particular geographic area.” Baker Hughes, 908 F.2d at 982; see Arch Coal, 329 F. Supp. 2d at
8
117. That showing establishes a presumption that the merger will substantially lessen
competition. Baker Hughes, 908 F.2d at 982. Defendants can then rebut this presumption by
demonstrating that the FTC’s prima facie case and market-share statistics inaccurately predict the
merger’s probable effects in the relevant market. Id. at 991. If Defendants’ rebuttal is
successful, the burden of producing further evidence of anticompetitive effects shifts to the FTC
“and merges with the ultimate burden of persuasion which remains with the [FTC] at all times.”
Id. at 983.
In addition to assessing the FTC’s prima facie case and any rebuttal evidence, in deciding
whether to grant preliminary injunctive relief, the Court must weigh the equities. Because the
public’s interest in effective enforcement of the antitrust laws is paramount, a “showing of
likelihood of success creates a presumption in favor of preliminary injunctive relief.” Heinz, 246
F.3d at 726. “Conversely, absent a likelihood of success on the merits, equities alone will not
justify an injunction.” Arch Coal, 329 F. Supp. 2d at 116.
The Supreme Court has also stressed that courts must judge “the probable anticompetitive
effects of the merger” “functionally” and based on “a further examination of the particular
market—its structure, history and probable future.” Gen. Dynamics, 415 U.S. at 498 (quoting
Brown Shoe Co. v. United States, 370 U.S. 294, 320–21 & n.38 (1962)) (cleaned up). Therefore,
“antitrust theory and speculation cannot trump facts, and even Section 13(b) cases must be
resolved on the basis of the record evidence relating to the market and its probable future.” Arch
Coal, 329 F. Supp. 2d at 116–17.
Analysis
A. The FTC’s Prima Facie Case
For the FTC to show a likelihood of success on the merits and justify a preliminary
injunction blocking the Evonik-PeroxyChem merger, it must first meet its prima facie burden by
9
(1) defining a relevant product market, (2) defining a relevant geographic market, and
(3) showing undue concentration in that combined market. Baker Hughes, 908 F.2d at 983.
1. Defining the Relevant Market
“The relevant market is the ‘area of effective competition’ within which the defendants
operate.” United States v. E. I. du Pont de Nemours & Co., 353 U.S. 586, 649 (1957) (quoting
Standard Oil Co. of Cal. v. United States, 337 U.S. 293, 299 n.5 (1949)). Defining the relevant
market is a “necessary predicate” to finding a Clayton Act violation because the proposed merger
“must be one which will substantially lessen competition within the area of effective
competition.” Id. at 593 (internal quotations omitted); see Baker Hughes, 908 F.3d at 982
(government must “show[] that a transaction will lead to undue concentration in the market for a
particular product”). The scope of the relevant market also dictates the analysis of market power
and the merger’s anticompetitive effects. See United States v. Sungard Data Sys., Inc., 172 F.
Supp. 2d 172, 181 (D.D.C. 2001); FTC v. Cardinal Health, Inc., 12 F. Supp. 2d 34, 45 (D.D.C.
1998). “The FTC bears the burden of proof and persuasion in defining the relevant market.”
FTC v. Arch Coal, Inc., 329 F. Supp. 2d 109, 119 (D.D.C. 2004).
A relevant market has two parts: a product market and a geographic market, Marine
Bancorp., 418 U.S. at 618. The relevant product market identifies the object of Defendants’
competition, and the relevant geographic market identifies where that competition takes place.
See Arch Coal, 329 F. Supp. 2d at 119.
The parties sharply contest both aspects of the relevant market. The FTC argues that the
relevant market is non-electronics grade hydrogen peroxide within two separate geographic
markets, the Pacific Northwest and the Southern and Central United States. Defendants argue
that both components of the FTC’s proposed market are overbroad and inconsistent with the
commercial realities of the industry. The Court agrees with Defendants that the FTC has not met
10
its burden of establishing its prima facie case because it has not identified a relevant market
within which to analyze the merger’s possible anticompetitive effects. That failure begins and
ends with the FTC’s theory of supply-side substitution, or “swinging,” a substantial departure
from the typical way in which a product market is defined.
a. The FTC’s Product Market and Alternative Product Markets
The Court begins with the FTC’s proposed product market for the sale of standard,
specialty, and pre-electronics grade hydrogen peroxide, which it calls the “non-electronics”
hydrogen peroxide market. PPFFCL at 84 ¶¶ 23–25.
Product markets are almost always defined by demand substitution. See Heinz, 246 F.3d
at 718; Wilhelmsen, 341 F. Supp. 3d at 45 (demand substitution the “touchstone” of product
market definition). Demand substitution describes “customers’ ability and willingness to
substitute away from one product to another in response to a price increase or a corresponding
non-price change such as a reduction in product quality or service.” Merger Guidelines § 4.
Demand substitution polices the “outer boundaries of a product market” and is governed by
either (1) consumers’ “reasonable interchangeability of use” or (2) the “cross-elasticity of
demand” (price sensitivity) between a product and substitutes for it. Brown Shoe, 370 U.S. at
325. When aggregating products into a relevant market, courts focus on demand substitution
because it illuminates whether customers can switch to one product and constrain
anticompetitive pricing in another. United States v. Aetna Inc., 240 F. Supp. 3d 1, 20 (D.D.C.
2017); see FTC v. Swedish Match, 131 F. Supp. 2d 151, 157 (D.D.C. 2000); Hill Hrg. Tr.
2076:15–25. For instance, if customers would switch from Jif peanut butter to Peter Pan
following a price increase, those two products are more likely to be included in a relevant
product market.
11
A relevant product market also “must be drawn narrowly to exclude any other product to
which, within reasonable variations in price, only a limited number of buyers will turn; in
technical terms, products whose ‘cross-elasticities of demand’ are small.” Times-Picayune Pub.
Co. v. United States, 345 U.S. 594, 612 n.31 (1953); see Arch Coal, 329 F. Supp. 2d at 120
(“Relevant market analysis is based on the ‘narrowest market’ principle.”); Merger Guidelines
§ 4.1.1 (product market defined based on “smallest relevant market satisfying the hypothetical
monopolist test”). For example, Jif may compete with mayonnaise “in the overall marketplace”
for sandwich spreads, but that does not necessarily mean both should “be included in the relevant
product market for antitrust purposes,” Staples I, 970 F. Supp. at 1075.
Courts use two approaches to help define a relevant product market. The first is the
“hypothetical monopolist test.” FTC & DOJ Horizontal Merger Guidelines (2010), § 4.1.1. The
test asks whether a hypothetical monopolist controlling the products in the alleged market could
profitably impose at least a small but significant and non-transitory increase in price (SSNIP),
generally assumed to be about five percent, on at least one product in the market. 2 FTC v.
Staples, Inc., 190 F. Supp. 3d 100, 121–22 (D.D.C. 2016) (Staples II). If a hypothetical
monopolist can profitably impose a SSNIP, the products may comprise a relevant market. Id. at
121. The second approach weighs the Brown Shoe factors: “industry or public recognition of the
[relevant market] as a separate economic entity, the product’s peculiar characteristics and uses,
2
The Merger Guidelines, while not binding on courts, offer persuasive guidance in examining
competitive effects. See Heinz, 246 F.3d at 716 n.9. They also recognize that a SSNIP may be
“larger or smaller than five percent” based on industry specifics, § 4.1.2, but the FTC’s
uncontested position is that a SSNIP of “about five percent” is appropriate. PPFFCL at 2 ¶ 5.
12
unique production facilities, distinct customers, distinct prices, sensitivity to price changes, and
specialized vendors.” Brown Shoe, 370 U.S. at 325; see Wilhelmsen, 341 F. Supp. 3d at 47.3
While the Merger Guidelines explicitly state that “[m]arket definition focuses solely on
demand substitution factors,” § 4, they provide an exception to that general rule when “supply
side substitution” may be used to aggregate products that are not demand substitutes into one
market, id. § 5.1 & n.8. Rather than relying on consumers’ ability to constrain prices, supply-
side substitution or elasticity focuses on suppliers’ responsiveness to price increases and their
ability to constrain anticompetitive pricing by readily shifting what they produce. See Rebel Oil
Co. v. Atl. Richfield Co., 51 F.3d 1421, 1436 (9th Cir. 1995); Rothman Rpt., JX0075-034
(aggregating products that are supply-side substitutes better “reflect[s] suppliers’ competitive
significance”). According to supply-side substitution theory, the higher the cross-elasticity of
supply—“the capability of . . . production facilities to be converted to produce a substitute
product”—“the more likely it is that the alternative products are to be counted in the relevant
market.” Cardinal Health, 12 F. Supp. 2d at 46; see Brown Shoe, 370 U.S. at 325 n.42 (“The
cross-elasticity of production facilities may also be an important factor in defining a product
market.”); Rothery Storage & Van Co. v. Atlas Van Lines, Inc., 792 F.2d 210, 218 (D.C. Cir.
1986) (same).
The Merger Guidelines offer a helpful shorthand for supply side substitution—
“swinging.” Suppliers are said to have “readily available ‘swing’ capacity” to “rapidly” enter a
product market—and therefore to constrain anticompetitive pricing—if “supply side substitution
3
“The Brown Shoe practical indicia may indeed be old school, and its analytical framework
relegated ‘to the jurisprudential sidelines.’ But Brown Shoe remains the law, and this court
cannot ignore its dictates.” FTC v. Sysco Corp., 113 F. Supp. 3d 1, 27 n.2 (D.D.C. 2015)
(quoting FTC v. Whole Foods Market, Inc., 548 F.3d 1028, 1059 (2008) (Kavanaugh, J.,
dissenting)) (cleaned up).
13
is” (1) “nearly universal among the firms selling one or more of a group of products,” (2) “easy,”
and (3) “profitable.” Merger Guidelines § 5.1 & n.8 (cleaned up); PPFFCL at 84–85 ¶ 24. The
parties’ experts “agree that proof of each of these three conditions is required before a relevant
product market may be defined based on supply-side considerations,” DPFFCL at 23 ¶ 68, and
the Court sees no reason to disagree.4 Rebel Oil offers a helpful illustration of supply-side
substitution. The court in that case grouped the sale of self-serve and full-service gasoline into
one relevant product market because it found that “sellers of full-serve gasoline can easily
convert their full-serve pumps, at virtually no cost, into self-serve, cash-only pumps, expanding
output and thus constraining any attempt by [the defendant] to charge [higher] prices for self-
serve gasoline.” 51 F.3d at 1436.
i. Swinging Between Standard, Specialty, and Pre-
Electronics Grade Hydrogen Peroxide
The FTC’s only basis for aggregating standard, specialty, and pre-electronics grade
hydrogen peroxide into a single market is supply-side substitution. Rhilinger Hrg. Tr. 2272:14–
16. The Court therefore turns to the evidence about whether suppliers’ swinging between
production of these grades is nearly universal, easy, and profitable, as set forth in the Merger
4
The 2010 Merger Guidelines’ reference to swinging postdates the very few cases that have
considered supply-side substitution, so those cases do not reference the three swinging
requirements. Nonetheless, the case law is generally consistent with them. See, e.g., Brown
Shoe, 370 U.S. at 366–68 (Harlan, J., dissenting in part, concurring in part) (swinging between
women’s and men’s shoes); United States v. Colum. Steel Co., 334 U.S. 495, 510–11 (1948)
(swinging production of different rolled steel products); Rebel Oil, 51 F.3d at 1436 (swinging
between offering full-service and self-serve gasoline); Virtual Maint., Inc. v. Prime Comput.,
Inc., 11 F.3d 660, 665 (6th Cir. 1993) (swinging between computer systems with and without
software updates included); FTC v. Elders Grain, Inc., 868 F.2d 901, 907 (7th Cir. 1989)
(swinging between variations of industrial dry corn); cf. FTC & DOJ Horizontal Merger
Guidelines §§ 1.32–1.322 (1997) (describing similar parameters for defining aggregate product
market based on supply side substitution).
14
Guidelines. The Court finds that the FTC has failed to meet its burden of showing that supply-
side substitution across these three grades meets any of the three requirements.
(A) Nearly Universal
The Court cannot conclude, as the FTC urges, that swinging across these grades—while
present to some degree—is “nearly universal” among the market participants. Merger
Guidelines § 5.1 n.8.
First, and most obviously, three of the five North American suppliers of hydrogen
peroxide do not, at present, swing to the production of pre-electronics grade hydrogen peroxide:
they simply do not produce that product. PeroxyChem and Solvay produce a purified hydrogen
peroxide “feedstock” that is a precursor to their production of electronics grade hydrogen
peroxide. Montag Hrg. Tr. 1528:1–5; Kramer Hrg. Tr. 1635:19–1636:7; Suter Hrg. Tr. 412:11–
17. But just because they further refine this feedstock to make electronics grade hydrogen
peroxide does not mean it is pre-electronics grade for swinging purposes. In fact, PeroxyChem
and Solvay do not market or sell their feedstock to customers as pre-electronics grade hydrogen
peroxide. JX0001-004, Hancock Declaration ¶¶ 22–23; Montag Hrg. Tr. 1531:23–1532:1; Suter
Hrg. Tr. 434:24–435:11. For that reason, they do not constrain the prices of pre-electronics
grade hydrogen peroxide sold by Evonik and Arkema.
Radlinski Hrg. Tr. 572:4–6, 572:18–23. Swinging is not nearly universal
between grades of hydrogen peroxide where a majority of suppliers do not swing into one of the
three grades.
Second, although all suppliers produce hydrogen peroxide for more than one end use,
some do not swing into specialty grade hydrogen peroxides formulated for specific end uses. For
example, Evonik does not sell an aseptic packaging product in the United States, and Nouryon
15
does not make one at all. Suter Hrg. Tr. 411:18–412:7; Corson Hrg. Tr. 597:14–22, 672:12–16;
PX2187–040. The tin stabilizer in Evonik’s hydrogen peroxide prohibits it from marketing a
chemical synthesis product and from obtaining EPA approval to market hydrogen peroxide
biocide products. Corson Hrg. Tr. 666:6–667:16; DX0348; PX1522-001 to -002; PX1055-001.
Some suppliers also do not swing into specialty grade hydrogen peroxide formulated for medical
sterilization, contact lens solution production, and rocket propulsion. DPFFCL at 87 ¶ 234
n.537.
The FTC tries to waive away this evidence by arguing that specialty grade hydrogen
peroxide formulated for those various end uses to which suppliers cannot swing comprises a
small percentage “of all H2O2 in North America.” PPFFCL at 16 ¶ 50. But the FTC decided to
include specialty grade hydrogen peroxide in its proposed product market, and this argument
says nothing about the ability—or inability—of various suppliers to swing into different
specialties. The FTC has not provided evidence, as it must to establish a product market based
on swinging across grades, see Arch Coal, Inc., 329 F. Supp. 2d at 119, that shows the portion of
the specialty grade market to which suppliers actually do swing. 5
Finally, it bears noting that much of what the FTC characterizes as swinging in the
hydrogen peroxide market is not the sort of activity that constrains prices in the way the Merger
Guidelines appear to intend. This is so because over time suppliers are moving overwhelmingly
5
Defendants also argue that swinging is not nearly universal because the hydrogen peroxide
manufacturing process limits suppliers from swinging 100 percent of their capacity to specialty
or pre-electronics grade hydrogen peroxide. See DPFFCL at 25 ¶ 74; id. at 32 ¶ 87. While this
may distinguish swinging in the hydrogen peroxide industry with swinging from the Fourdrenier
paper machine, not all capacity necessarily needs to swing into a substitute market in order to
constrain anticompetitive prices. To constrain prices for specialty or pre-electronics grade
hydrogen peroxide, a minority of the overall hydrogen peroxide market, see Rothman Hrg. Tr.
755:21–25, suppliers need only purify a fraction of their standard grade hydrogen peroxide.
16
in one direction toward higher purity products that are more profitable. In fact, Defendants’
expert, Dr. Nicholas Hill, persuasively testified that a supplier’s adjustments described above—
the “strategic decision to sell more of one of its products and less of another . . . in one
direction”—is not swinging under the Guidelines. Hill Hearing Tr. 2078:7–10 (emphasis
added). Rather, swinging “means to move back and forth producing those products”—like a
swing. Id. 2077:24–2078:6. Dr. Hill’s prototypical swinging example is the Fourdrenier paper
machine. Id. 2079:17–18. The machine shifts between producing containerboard for cardboard
boxes and kraft paper for grocery bags. Id. 2079:6–2080:1. Of course, cardboard boxes and
grocery bags are not demand substitutes, but based on the relative profitability of those two
products at any given time, the supplier “swings” between the two “at the touch of a button.” Id.
Dr. Hill’s conception of swinging “back and forth” is intuitive and tracks the few cases to
recognize supply substitution; the Fourdrenier paper machine is like the retailer swinging
between full-service and self-serve gasoline in Rebel Oil, 51 F.3d at 1436.
In contrast, the record suggests that the market for hydrogen peroxide reflects a long-term
shift in production in one direction, toward high-purity, specialized products that are more
profitable. See, e.g., JX0151-016
id. -017
Rettig Hrg. Tr. 1047:10–15 (Evonik “focusing on specialty chemicals” because they
“promise higher returns in terms of profitability.”). At the same time, suppliers are moving away
from the shrinking pie that is the pulp and paper industry. As a result, these shifts in production
are not as likely to constrain anticompetitive prices downward, for example, for standard grade
17
hydrogen peroxide, as would be the case if suppliers more commonly swung both back and forth
between grades.
For these reasons, the record does not support the conclusion that swinging across
standard, specialty, and pre-electronics grade hydrogen peroxide is nearly universal.
(B) Easy
Similarly, the Court cannot conclude that swinging across all these grades—while in
some cases relatively simple—is generally “easy” for purposes of analyzing competition in the
hydrogen peroxide market.
The Merger Guidelines’ section that references swinging lacks a definition for “easy,”
§ 5.1, but later on, the Guidelines describe “easy” entry into a market as “timely, likely, and
sufficient in its magnitude, character, and scope to deter or counteract the competitive effects of
concern,” § 9.6 These standards reflect why courts consider supply substitution in product
market definition—to assess if suppliers can constrain anticompetitive prices.
The record is clear that it is easy for some suppliers, merely as a matter of production
mechanics, to swing some capacity up-grade or down-grade between standard, specialty, and—
for the two suppliers who currently market pre-electronics—pre-electronics grade hydrogen
peroxide. Suter Hrg. Tr. 406:9–14; Myrick Hrg. Tr. 485:24–486:11; Radlinski Hrg. Tr. 539:16–
19; Hamann Hrg. Tr. 1322:3–19; Kramer Hrg. Tr. 1685:8–14, 1686:10–13, 1696:4–10, 1696:25–
1698:8. Evonik admitted as much to regulators before the FTC moved for a preliminary
injunction. See PX0019-010 (“some” diversion from specialty to standard grade hydrogen
6
An earlier version of the Merger Guidelines—which does not use the word “easy” to describe
product market definition by supply substitution—suggests that swinging into the “production
and sale of the relevant product” must take place “within one year” in response to a SSNIP in the
relevant product. Merger Guidelines § 1.321–1.322 (1997); see also id. § 1.321 n.14.
18
peroxide “could be easily and quickly accomplished at no significant cost”); PX1201-012
( ).
But in many other cases, the evidence is just as clear that it is not easy for a given
supplier to swing into a given grade. Although suppliers can swing 100 percent of their capacity
down-grade, Hill Hrg. Tr. 2165:22–2166:4, the manufacturing process limits how much can
swing up-grade; a plant can only commit to percent of output to specialty grade hydrogen
peroxide, and only percent of that specialty grade can be purified into pre-electronics grade,
leaving around pounds of pre-electronics grade hydrogen peroxide for every 100 pounds of
crude. ; ;
; JX0151-015. As discussed above, this limitation does not necessarily stop
suppliers from constraining prices across grades. That said, it does make it difficult
7
The FTC argues that it is easy for the three suppliers who do not market pre-electronics
grade hydrogen peroxide to swing into that market. Indeed, some of Evonik’s submissions to
regulators give the same impression:
PX0002-031; PX1201-012. And in
general, the technology required to produce pre-electronics grade is not substantially different
from the technology required to produce lower-grade hydrogen peroxide. See
; PX1387-010 to -017.
7
See DPFFCL at 25–26 ¶¶ 72, 75.
19
But the reality is much more complicated. Producing pre-electronics grade hydrogen
peroxide requires additional equipment, including a second reverse osmosis unit, additional
testing (several times a day) to ensure the equipment is working, specially trained personnel, a
specially equipped room and laboratory, and
. Hamann Hrg. Tr. 1282:3–1286:16. Evonik has years of experience
supplying pre-electronics grade hydrogen peroxide to MGC from its plant in Mobile, Alabama,
and it still cost the company over more than to upgrade its Gibbons,
Alberta, plant to supply the same product. See Costanzo Hrg. Tr. 1136:5–1137:3, 1144:11–
1145:9 ( ); Hamann Hrg. Tr. 1326:25–1327:14; PX0002-031. And all of
that assumes the supplier even has the technical know-how to produce pre-electronics grade
hydrogen peroxide, far from a given. Were a supplier like —which has never tried to
produce pre-electronics grade, , likely because of the
complexity and costs just described—to try to swing into that market, the effort would be
anything but “timely, likely, [or] sufficient” to constrain prices. Merger Guidelines § 9.
Counterintuitively, it is also not easy for PeroxyChem or Solvay—which make
electronics grade hydrogen peroxide—to swing into pre-electronics grade, either. The FTC
produced some evidence that PeroxyChem may be able to market its electronics feedstock as pre-
electronics grade hydrogen peroxide. But MGC—“the largest customer for pre-electronics[,]
which buys on the order of 99 percent of pre-electronics that’s sold,” Hill Hrg. Tr. 2080:22–23;
see also JX0001-001—has never approved feedstock as satisfactory
pre-electronics grade hydrogen peroxide after years of trying on their part. See PPFFCL at 10–
20
11 ¶¶ 32–33.8 It is exceedingly difficult for
pre-electronics hydrogen peroxide, PX0002-031, a product for which suppliers measure
impurities in “parts per billion,” Hamann Hrg. Tr. 1281:13. See DPFFCL at 26–27, 29 ¶¶ 77–78,
81. That includes PeroxyChem and Solvay, even though they sell electronics grade hydrogen
peroxide, it is not easy for them to sell pre-electronics grade. A world-renowned baker may sell
birthday cakes; it does not mean he can come close to swinging into the cake-mix market if Betty
Crocker decides to raise prices. Mahr Hrg. Tr. 2327:13–16. 9
For these reasons, the Court cannot conclude that swinging across standard, specialty,
and pre-electronics grade hydrogen peroxide is easy.
(C) Profitable
Finally, the FTC has not met its burden of showing that swinging between grades of
hydrogen peroxide is likely to be profitable, because swinging down-grade is, in general, not
profitable. See Merger Guidelines § 5.1. In other words, suppliers’ average profits increase so
much up-grade that even if the price of standard grade or specialty grade increased by five or
8
An internal Evonik document could be construed to suggest that Evonik considers PeroxyChem
and Solvay competitors for pre-electronics grade H2O2, see PPFFCL at 12 ¶ 35 (citing PX1156-
010), but the better reading of that chart is that it represents the entire electronics market, with
Arkema and Evonik’s slices meant to signify the pre-electronics hydrogen peroxide they supply
to MGC. See DPFFCL at 27 ¶ 79.
9
The parties also contest the difficulty of Evonik and PeroxyChem’s swinging between grades of
hydrogen peroxide in a manner that does not necessarily bear on the market’s ability to constrain
prices post-merger because it does not impact other suppliers’ ability to constrain a post-merger
Evonik. It is difficult for Evonik to swing into tin-free hydrogen peroxide products and aseptic
packaging, but PeroxyChem currently and easily swings into each of these end uses, see Montag
Hrg. Tr. 1516:20–1517:19, 1522:9–25, and so will a post-merger Evonik. Similarly, it is
difficult for PeroxyChem to swing into pre-electronics grade hydrogen peroxide, but Evonik
already markets pre-electronics hydrogen peroxide, see JX0001-002. Evidence of
PeroxyChem’s ability to break into that market is therefore only relevant to the extent that it
reflects swinging difficulties faced by other suppliers
PPFFCL
at 10–11 ¶¶ 32–33.
21
even ten percent, suppliers are unlikely to switch production down-grade from specialty or pre-
electronics grade hydrogen peroxide.
For example, Evonik’s average profit margins per pound of hydrogen peroxide are about
cents for standard grade, cents for specialty grade ( percent higher than standard grade),
and cents for pre-electronics grade ( percent higher than standard grade and percent
higher than specialty grade). JX0066-043 fig. 10; Costanzo Hrg. Tr. 1143:5–1144:1, 1176:14–
19 (selling standard grade instead of pre-electronics “would be a disaster on the investment
economics” and “the intent [is] to sell it as specialty”). Other suppliers’ margins similarly
increase up-grade. See ; JX0151-022 (showing
specialty grade with percent higher profit margin than standard grade, pre-electronics grade
with percent higher than standard grade and percent higher than specialty grade); Lerner
Hrg. Tr. 1377:9–20 (swinging production from specialty to standard grade hydrogen peroxide
would be “economic suicide” and “make[] no commercial, business or any logical sense”).
The FTC objects to using average profit margins to judge profitability. Its expert, Dr.
Dov Rothman, found that some standard and specialty grade hydrogen peroxide products sell at a
higher margin than some higher-grade products,10 likely because of regulatory or customer-
10
[F]or percent of Evonik’s volume of food grade hydrogen peroxide, Evonik’s
per unit margin is higher than Evonik’s average per unit margin on pre-electronics
grade; for percent of Evonik’s volume of cosmetics grade hydrogen
peroxide, Evonik’s per unit margin is higher than Evonik’s average per unit
margin on pre-electronics grade; for percent of Evonik’s volume of hydrogen
peroxide for teeth whitening, Evonik’s per unit margin is higher than Evonik’s
average per unit margin on pre-electronics grade. Furthermore, while food grade,
cosmetics grade and hydrogen peroxide for teeth whitening are relatively low
volume products for Evonik, for every 100 units of pre-electronics grade
hydrogen peroxide that Evonik sells, it sells units of standard grade hydrogen
peroxide at a per unit margin that is higher than its average per unit margin on
pre-electronics grade.
22
focused specifications. There are three reasons why the Court cannot find that this evidence
means that swinging down-grade is generally profitable, such that it is appropriate to lump
standard, specialty, and pre-electronics grade hydrogen peroxide together in a single product
market.
First, the FTC has provided no data on what percentage of the standard and specialty
grade markets are comprised of these supposed high-profit-margin products to which suppliers
could swing. Second, this subset of high-margin standard and specialty grade products increases
the average margins for those products, thereby masking what otherwise would be even starker
profitability differences between grades. Third—and key for assessing the ability of suppliers to
constrain prices—if suppliers wanted to produce more higher-margin standard or specialty grade
products, they would not do so by swinging down-grade from their profitable stock of specialty
and pre-electronics grade hydrogen peroxide. They would instead try to convert their existing
stock of lower-margin standard and specialty grade hydrogen peroxide to higher-margin
products. Hill Hrg. Tr. 2083:2–21; see (if demand increased
for standard grade hydrogen peroxide, “we would just supply them from our production of
standard product,” not from pre-electronics grade product). This is consistent with suppliers’
long-term shift in production toward more profitable, specialized, and high-purity products
described above.
At closing argument, the FTC argued that swinging does not have to be profitable
“between every combination of products” and that a “snapshot in time” of current contracts and
profitability could be misleading. Rhilinger, Hrg. Tr. 2395:14–2396:7. The Court does not
Rothman Rebuttal Rpt., PX7102-017; see also Rothman Hrg. Tr. 791:24–792:19.
23
mean to suggest that swinging must be profitable between every combination of products to meet
this requirement. But here, there are consistent and significant profitability differences between
selling standard, specialty, and pre-electronics grade hydrogen peroxide. And based on that
record, including the overall trend in the market, the Court cannot conclude that in response to a
SSNIP on standard or specialty grade hydrogen peroxide, suppliers would likely swing down-
grade and constrain those prices; the profit margins are, in general, simply too much higher in
higher grades.
To be sure, these differences in profitability suggest that suppliers may constrain
anticompetitive prices in specialty or pre-electronics grade by swinging up from lower-margin
standard grade hydrogen peroxide. But as discussed above, suppliers do not swing up-grade
nearly universally because it is not easy. See Hill Rpt., JX0066-043 (“The rewards to producing
pre-electronics grade are already so high that firms that do not produce it likely do not do so for
reasons that will not change in response to a small price increase.”). And all three swinging
requirements must be met to aggregate grades of hydrogen peroxide in a relevant product
market.11
For all the above reasons, the FTC cannot combine standard, specialty, and pre-
electronics grades in a relevant product market to analyze the anticompetitive effects of the
proposed merger. Therefore, the FTC’s proposed relevant product market does not support its
prima facie case.
11
The FTC also argues that its proposed market satisfies the hypothetical monopolist test
because consumers would not substitute away from non-electronics hydrogen peroxide to other
chemicals. See, e.g., PFFCL at 85 ¶ 25. That cannot save the FTC’s overbroad market. The
hypothetical monopolist test “is designed to ensure that candidate markets are not overly
narrow.” Merger Guidelines § 4; see also id. § 4.1.1 (test “does not lead to a single relevant
market”). It says nothing about whether a market is overly broad.
24
ii. Alternative Product Markets
Defendants argue that this failure means the Court need go no further: without a relevant
product market, the FTC cannot succeed. See Mahr Hrg. Tr. 2401:22–2402:13. The FTC could
have pleaded or argued for alternative markets, they say, but it did not, and “it’s not the Court’s
job to go around and try to find that correct market.” Mahr Hrg. Tr. 2402:8–13 (cleaned up).
And the FTC candidly recognizes that it has “not alleged in [the] complaint a market for
standard-grade hydrogen peroxide or any other, sort of, combination of products.” Rhilinger
Hrg. Tr. 2389:16–18; see Compl. ¶¶ 23–24 (“The relevant product market in which to assess the
effects of the Acquisition is hydrogen peroxide,” excluding “electronics grade hydrogen
peroxide.”).
Defendants’ argument is not without support. The FTC has the burden to prove a
relevant product market when it seeks a preliminary injunction, see Arch Coal, 329 F. Supp. 2d
at 120, a point with which the FTC does not quibble, see Rhilinger Hrg. Tr. 2389:9–10 (“the case
law says that we need to prove a relevant market in which we can show harm”). This is so
because without a relevant product market, the FTC cannot show a likelihood of ultimate success
on its claim under the Clayton Act. See 15 U.S.C. § 18 (prohibiting acquisitions whose “effect
. . . may be substantially to lessen competition” in “any line of commerce”); Heinz, 246 F.3d at
719 n.17 (“Courts interpret ‘line of commerce’ as synonymous with the relevant product
market.”); see FTC v. Whole Foods Market, Inc., 548 F.3d 1028, 1036 (2008) (Brown, J.)
(“market definition is . . . necessary in a § 7 case” (citing 15 U.S.C. § 18)). 12
12
The D.C. Circuit’s Whole Foods decision lacked a majority opinion. See Whole Foods, 548
F.3d at 1051 n.1, 1061 n.8 (Kavanaugh, J., dissenting). Thus, in referring to one of the two
concurring opinions or the dissent, the Court will indicate the name of the Judge whose opinion
is cited. See id. at 1032 (Brown, J.); id. at 1041 (Tatel, J.); id. at 1051 (Kavanaugh, J.,
dissenting).
25
But just because the relevant product market is not “as broad[] as the Government
chooses to define it,” the record may still contain evidence of an alternative relevant product
market in which to analyze the merger’s competitive effects. Brown Shoe, 370 U.S. at 368
(Harlan, J., dissenting in part, concurring in relevant part). “The duty rests with the District
Court . . . to determine what is the appropriate market on an appraisal of the relevant economic
considerations.” Id. And despite the FTC’s insistence that the relevant product market should
not “be defined around individual grades of H2O2 or end uses,” Br. at 14, it has provided
quantitative evidence of alleged anticompetitive harm in a narrower alternative market consisting
solely of standard grade hydrogen peroxide in the Southern and Central United States. See
Rothman Rpt., JX0075-052 & n.159, -094 & n.324, -104 & n.350 (providing market
concentration statistics, predicted first order approximation price effects, and merger simulation
predicted price effects, assuming that PeroxyChem divests its Prince George facility to a new
competitor). The parties also agree that hydrogen peroxide formulated for particular end uses
could constitute separate product markets, see PPFFCL at 3, 5 ¶¶ 11, 15; DFFCL at 21–22
¶¶ 62–63, though the FTC has not provided any specific data related to end uses with which to
evaluate the merger. The Court thus proceeds to consider the evidence in the record as to
whether either (1) standard grade hydrogen peroxide or (2) hydrogen peroxide formulated for
specific end uses is a relevant product market for purposes of assessing the merger’s competitive
effects.13
13
The record lacks evidence of market concentration statistics or other quantitative measures of
anticompetitive effects for alternative specialty grade or pre-electronics grade hydrogen peroxide
product markets.
26
(A) Standard Grade Hydrogen Peroxide
Standard grade hydrogen peroxide serves various end uses, including the bleaching of
pulp, paper, and textiles; it is also used in wastewater treatment and in the mining and oil and gas
industries. Dumas Hrg. Tr. 235:1–3; Suter Hrg. Tr. 408:8–14; Costanzo Hrg. Tr. 1223:6–13;
Montag Hrg. Tr. 1566:5–1567:2, 1600:23–1601:3. It is often referred to as a “commodity”—a
product that can be used interchangeably among suppliers with ease, where they compete mainly
on price. See PPFFCL at 34 ¶ 120; DPFFCL at 8 ¶ 15; JX0120-001; Anderson Hrg. Tr. 193:1–
18. However, this does not necessarily mean that all standard grade hydrogen peroxide,
regardless of end use, constitutes a relevant product market. See Arch Coal, 329 F. Supp. 2d at
120 (describing “the ‘narrowest market’ principle”). For that, there must be sufficient demand-
side substitution among standard grade products, or—as discussed above—supply-side
substitution may suffice in the exceptional case if the Merger Guidelines’ swinging requirements
are met.
On the demand side,“[d]etermination of the competitive market for commodities depends
on how different from one another are the offered commodities in character or use, how far
buyers will go to substitute one commodity for another.” E. I. du Pont., 351 U.S. at 393; see
Staples I, 970 F. Supp. at 1074. The FTC has not argued that there is demand-side
substitutability across formulations of standard grade hydrogen peroxide. 14 And perhaps for that
14
While the FTC has consistently pleaded and argued for a product market consisting of non-
electronics grade hydrogen peroxide, Defendants contend that the FTC’s swinging theory only
arose after it moved for a preliminary injunction:
This supply side approach didn’t arise until Dr. Rothman’s report after the fact
discovery was closed. There is no mention in the complaint of supply side factors
informing product market definition, none. There’s no mention of the word
“swing” or “shift” anywhere in the FTC’s complaint. They ask no discovery of
any of the five suppliers leading up to -- in the discovery leading up to the
hearing, anything about their ability to shift or swing.
Mahr Hrg. Tr. 2321:8–15.
27
reason, there is no evidence in the record that buyers are likely “to substitute one commodity for
another” in response to a SSNIP for a particular end use. Staples I, 970 F. Supp. at 1074. For
example, if a customer for standard grade hydrogen peroxide used in in fracking—removing oil
and gas from subterranean rocks and fissures—experienced a SSNIP, the record does not show
that she is likely to instead purchase standard grade hydrogen peroxide intended for bleaching
pulp and paper. While all standard grade hydrogen peroxide has a similar purity and chemical
composition, its “character or use” appears sufficiently different across end uses. Id. To the
extent the record contains evidence on this point at all, it suggests that customers primarily view
standard grade hydrogen peroxide produced by different suppliers as interchangeable within—
but not between—end uses. See, e.g., Maeder Hrg. Tr. 170:16–172:5 (pulp and paper end use);
Engram Hrg. Tr. 317:2–11, 361:21–362:24 (wastewater treatment end use); PPFFCL at 13 ¶ 42
(oil and gas end use); PPFFCL at 4 ¶ 12 (“The precise combination of purity level, concentration,
and stabilization package varies depending on the [end use] of H2O2, but within each [end use],
H2O2 sold by each producer is very similar.”). Therefore, the different end-use products are not
demand substitutes, and they cannot be aggregated into a single standard grade product market
on that basis.15
The Court thus turns to the swinging exception to the usual demand-side rule. Merger
Guidelines § 5.1; see Heinz, 246 F.3d at 718 (“The definition of product market focuses solely
15
The Brown Shoe practical indicia also weigh against a standard grade market. The hydrogen
peroxide industry recognizes “well-defined submarkets” by end use; end uses within standard
grade, by their definition, have “peculiar characteristics and uses”; their customers tend to be
different (save for distributors who re-sell hydrogen peroxide into various industries); and prices
are distinct. Brown Shoe, 370 U.S. at 325; see, e.g., PPFFCL at 4 ¶ 12; Dumas Hrg. Tr. 235:1–3;
PX2047-031 (standard grade hydrogen peroxide for mining sells at nearly 15 percent higher
price than for pulp and paper bleaching); JX0083-065 to -118 (Evonik’s competitor details
database).
28
on demand substitution factors.” (cleaned up)). Under the Merger Guidelines, swinging within
standard grade hydrogen peroxide formulations must be nearly universal, easy, and profitable
before those products may be aggregated into one market. See § 5.1 & n.8.
The record is not totally clear on the ease and near universality of swinging between the
various formulations of standard grade hydrogen peroxide. This is likely so because the FTC
never proposed such a product market; it only argued these points to support swinging between
standard, specialty, and pre-electronics grades. But the evidence suggests that as a practical
matter, such swinging is possible and happens to some extent. See PPFFCL at 4 ¶ 12; PX1201-
012. Many of the obstacles to swinging between grades, explained above, do not apply to
swinging between the various formulations of standard grade. And most suppliers already make
the various formulations required for bleaching pulp, paper, and textiles; for treating wastewater;
and for use in the mining and oil and gas industries. See JX0083-065 to -118 (Evonik’s
competitor details database).
The problem is the lack of record evidence on profitability. The Court cannot find that
standard grade hydrogen peroxide is a relevant product market because the record lacks evidence
that swinging between standard grade formulations is likely to be profitable. In fact, the limited
evidence in the record suggests substantial differences in profitability across standard grade
formulations. Dr. Rothman found that “for every 100 units of pre-electronics grade hydrogen
peroxide that Evonik sells, it sells units of standard grade hydrogen peroxide at a per unit
margin that is higher than its average per unit margin on pre-electronics grade,” Rothman
Rebuttal Rpt., PX7102-017; see also Rothman Hrg. Tr. 791:24–792:19. The average profit
margin for Evonik’s standard grade hydrogen peroxide is about cents, and the profit margin
for its pre-electronics grade hydrogen peroxide is cents. JX0066-043 fig. 10. That means a
29
subset of standard grade hydrogen peroxide sells at a profit margin percent higher than the
average for standard grade. And of course, that means that some standard grade hydrogen
peroxide sells for even more than the percent higher profit margin than other standard grade
formulations, like that for pulp and paper bleaching, which has some of the lowest margins. See,
e.g., Anderson Hrg. Tr. 199:23–25; Lerner Hrg. Tr. 1379:13–24, 1381:6–18. Admittedly, the
evidence in the record on this point is minimal.16 But it is the FTC’s burden to define the market
and, if relying on supply-side substitutability, show that swinging is likely profitable. The
evidence does not suggest that in response to a SSNIP of five percent in lower-profit standard
grade hydrogen peroxide, suppliers likely would swing from higher-profit standard grade to
constrain the price for the lower-profit formulation.
And as described above, this shortcoming reflects a more fundamental issue with the
FTC’s overall product market definition. To some degree, suppliers’ decisions to make different
hydrogen peroxide products does not appear to represent swinging at all, because in general, it is
only profitable to shift production in one direction to more specialized products that “are more
stable in economic downturns” relative to pulp and paper products. Rettig Hrg. Tr. 1047:14–15;
see, e.g., JX0151-016 to -017; Once that happens, there
is no evidence that, in general, suppliers shift back, or that it would be profitable to do so in
response to a SSNIP. In other words, this is not an industry of suppliers prepared to swing and
constrain prices across lower-profit formulations, even within an alternative market for standard
grade hydrogen peroxide.
16
The record does include some evidence on pricing for standard grade, see, e.g., PX2047-031;
Hill Rpt. JX0066-098 fig. 45, but the Court is unable to glean from that data the profit margins
for each product, which is the relevant metric to assess whether suppliers are likely to swing. Cf.
Rebel Oil, 51 F.3d at 1436 (“it is immaterial that . . . a price differential exists” between supply-
substitutable products).
30
(B) End Uses of Hydrogen Peroxide
At this point, then, the FTC has not proven its proposed relevant product market for all
non-electronics grade hydrogen peroxide. Neither has it shown, in the alternative, a relevant
market for standard grade. Moving one last step narrower, the evidence in the record does
support a relevant product market for hydrogen peroxide based on traditional demand
substitutability: hydrogen peroxide products formulated for different end uses, regardless of
grade.17
The record is reasonably clear that “within any given end-use for H2O2, the product
offerings of the five H2O2 suppliers are largely undifferentiated.” PPFFCL at 33 ¶ 118. And in
contrast, across end uses, customers do not find the products substitutable. For example, most
suppliers make a specialty grade product used to preserve food packaged for sale known as
aseptic packaging hydrogen peroxide. Customers for that product do not view standard grade
hydrogen peroxide intended for pulp and paper bleaching as interchangeable with it. Similarly,
there is no reason to suspect that, in response to a price increase, they would switch from
hydrogen peroxide for aseptic packaging to that intended for bleaching. See Engram Hrg. Tr.
364:7–13; Suter Hrg. Tr. 429:2–25; Montag Hrg. Tr. 1516:20–1518:6; Rhilinger Hrg. Tr.
2272:11–13 (“Nobody here is arguing that you should bleach your hair or whiten your teeth or
clean your cuts with [hydrogen peroxide for] rocket fuel.”). Each of these product markets for
particular end uses are the “smallest relevant market[s] satisfying the hypothetical monopolist
test.” Merger Guidelines § 4.1.1; see PPFFCL at 3, 5 ¶¶ 11, 15; DFFCL at 21–22 ¶¶ 62–63.
Accordingly, hydrogen peroxide products formulated for the same end use satisfy a demand-side
17
PX1201-012
31
substitution approach to defining a relevant product market; analysis of the supply side is
unnecessary. See Heinz, 246 F.3d at 718.
b. The FTC’s Proposed Geographic Markets
To establish a prima facie case by showing that the merger would cause a highly
concentrated market, besides defining a relevant product market, the FTC must also demonstrate
a relevant geographic market. Baker Hughes, 908 F.2d at 982. The FTC proposes two relevant
geographic markets: (1) the Pacific Northwest, which includes Idaho, Oregon, Montana,
Washington, and Wyoming in the United States and Alberta, British Columbia, Manitoba, and
Saskatchewan in Canada; and (2) the Southern and Central United States, which includes
Alabama, Arkansas, Arizona, California, Colorado, the District of Columbia, Delaware, Florida,
Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota,
Missouri, Mississippi, North Carolina, North Dakota, Nebraska, New Mexico, Nevada, Ohio,
Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, and
West Virginia. PPFFCL at 22–23, 25 ¶¶ 72, 78.
As discussed below, any anticompetitive effects of the merger in the proposed Pacific
Northwest geographic market are resolved by PeroxyChem’s proposed divestiture of its Prince
George plant. And the FTC’s failure to show that non-electronics hydrogen peroxide is a
relevant product market makes the proposed Southern and Central United States geographic
market useless to the FTC in meeting its burden.
i. The Pacific Northwest and the Prince George
Divestiture
Within days of the FTC moving for a preliminary injunction, Evonik and PeroxyChem
agreed on a divestiture that threw a wrench in the FTC’s argument that their merger will
substantially lessen competition in its proposed Pacific Northwest geographic market.
32
Defendants agreed that if their merger closes, Evonik will not acquire PeroxyChem’s only plant
in that market, in Prince George, British Columbia. Instead, a new competitor, international
chemical manufacturer UI, will purchase the plant for . Share Purchase Agreement,
JX0147-017. Without analyzing the agreement with UI specifically, the FTC’s expert, Dr.
Rothman, concluded that if PeroxyChem sells its Prince George plant to a new competitor that
replaces PeroxyChem’s competitive intensity in the Pacific Northwest, competition will not be
substantially lessened in that geographic market. Rothman Rpt., JX0075-052 n.156, -104
nn.351–52; Rothman Hrg. Tr. 830:20–831:11. 18 The Court therefore turns to that threshold
question first.
Defendants have the burden to show that a proposed divestiture will replace the merging
firm’s competitive intensity. Aetna Inc., 240 F. Supp. 3d at 60. To evaluate whether a
divestiture will do so, courts consider the likelihood of the divestiture; the experience of the
divestiture buyer; the scope of the divestiture, the independence of the divestiture buyer from the
merging seller, and the purchase price. Id. at 60–74; FTC v. Sysco Corp., 113 F. Supp. 3d 1, 72–
78 (D.D.C. 2015). The Court holds that Defendants have met their burden of showing that UI
will replace PeroxyChem’s competitive intensity.
(A) Likelihood of the Divestiture’s Closing
For starters, the Prince George divestiture to UI is highly likely to occur. The parties to
the divestiture, Evonik, PeroxyChem, and UI, have agreed to use all commercially reasonable
efforts to ensure the closing conditions are satisfied; UI is capable of closing financially; it is
excited to get “a really good business at a really good price”; and just days ago, the Canadian
18
Dr. Rothman did not analyze what impact a divestiture to a new competitor would have on the
likelihood of anticompetitive coordinated effects in the Pacific Northwest. Even so, there is no
basis in the record to conclude that UI would be any more likely than PeroxyChem to coordinate
with suppliers in the Pacific Northwest to substantially harm consumers.
33
Competition Bureau entered into a Consent Agreement with Evonik approving both its merger
with PeroxyChem and the divestiture of the Prince George plant to UI. The Canadian authorities
found that the divestiture eliminated what would otherwise have been a likely “substantial
lessening of competition” in western Canada. Consent Agreement (Jan. 13, 2020), ECF No.
141-1 at 1–2, 10, 12–13;19 see Cummins Hrg. Tr. 1743:21–25, 1744:8–1746:7, 1770:11–17;
DX0142-006; DX0143-002; Share Purchase Agreement, JX0147-035, -038 to -041, -066. The
record lacks any significant obstacles to closing.
(B) UI’s Experience
The record shows that UI has the experience necessary to compete effectively in the
hydrogen peroxide industry. UI is an international supplier of organic peroxides and persulfates
that operates plants around the world, including a hydrogen peroxide plant in Turkey that it
bought in August 2019. PPFFCL at 65 ¶ 220; DPFFCL at 48 ¶ 127. Although it does not sell
hydrogen peroxide in North America, UI has long been a customer for hydrogen peroxide, using
it as a raw material in many of its products and serving many of the same customers that it would
19
Under Fed. R. Civ. P. 201(b)(2) and (c)(2), the Court takes judicial notice of the following
adjudicative fact apparent from the Consent Agreement signed January 13, 2020, by the
Commissioner of Competition and Evonik: The Commissioner of Competition of the Canadian
Competition Bureau has reached a Consent Agreement with Evonik to approve its merger with
PeroxyChem and the divestiture of the Prince George plant to United Initiators. See Consent
Agreement, ECF No. 141-1 at 1–2, 10, 12–13, 27; Defendants’ Request for Judicial Notice, ECF
No. 141. The Commissioner found that UI satisfied these requirements:
Consent Agreement, ECF No. 141-1 at 10, 12–13. The Court
takes judicial notice solely for the purpose of evaluating the likelihood of the divestiture’s
closing; after Canadian regulatory approval, the divestiture is now more likely to do so.
34
serve as a hydrogen peroxide supplier. DPFFCL at 48 ¶ 128. At its three North American
chemical plants, UI grapples with challenges much like those that hydrogen peroxide suppliers
face, such as security of supply, inventory, tracking, forecasting, and distribution. Id. ¶ 129;
Cummins Hrg. Tr. 1722:4–10. Jonathan Cummins—UI’s Vice President of Manufacturing for
the Americas, who will oversee the Prince George plant if the divestiture closes—managed a
hydrogen peroxide plant for Nouryon’s predecessor for seven years. DPFFCL at 49–50 ¶¶ 131,
135; Cummins Hrg. Tr. 1722:11–21. That wealth of experience is an important component in
helping UI replace PeroxyChem’s competitive intensity in the Pacific Northwest.
(C) The Divestiture’s Scope
The scope of the proposed divestiture is more than sufficient for UI to replace
PeroxyChem in effectively running the Prince George plant. The employees running the Prince
George plant’s day-to-day operations will continue to do so on UI’s behalf. DPFFCL at 50
¶ 135. UI will receive all tangible and intangible assets that it needs to compete—“key
production, sales, market, and distribution assets, sales and marketing personnel, and intellectual
property”—and PeroxyChem’s customers for the Prince George plant will become UI’s
customers . Id. ¶ 134.
The FTC challenges the divestiture’s scope on several grounds. It argues that UI is
buying a “standalone plant” and not a “standalone business” in Prince George. See DPFFCL at
50 ¶ 133; Rhilinger Hrg. Tr. 2427:14–22; Mahr Hrg. Tr. 2430:15–2431:3. It is true that
Defendants technically only propose a divestiture of the Prince George plant, but the evidence
shows that the plant “comes along with . . . everything else that’s needed to run a stand-alone
business.” Mahr Hrg. Tr. 2431:1–3. UI will have the “personnel, customer lists, information
systems, [and] intangible assets,” that will help to “effectively preserve the competition that
would have been lost through the merger.” Aetna, 240 F. Supp. 3d at 60 (internal citation
35
omitted).20 In that sense, UI is buying something more like an ongoing business than a plant.
And in a recent study of merger remedies, the FTC found that “all of the divestitures involving
an ongoing business succeeded” in “clearing a high bar—maintaining competition in the relevant
market.”21
The FTC also points out that PeroxyChem recently lost its biggest customer served by the
Prince George plant, Suncor. PPFFCL at 67 ¶ 229. But the Suncor issue speaks more to
competition already lost by PeroxyChem, rather than to whether UI will “replace the competitive
intensity lost as a result of the merger.” Sysco, 113 F. Supp. 3d at 74. Even setting that point
aside, PeroxyChem showed at the evidentiary hearing that it has already exceeded internal 2020
bidding projections for the Prince George plant by replacing more than half of the lost Suncor
business. Lerner Hrg. Tr. 1394:21–1395:15; Cummins Hrg. Tr. 1760:22–1761:13. Since the
hearing, PeroxyChem has had every incentive to continue these efforts, with the serious risk that
this Court or the Canadian Competition Bureau would block the merger and the need for the
divestiture to UI. Lerner Hrg. Tr. 1395:5–15. And if there were any remaining doubt about the
Prince George plant’s sustainability, the divestiture agreement
20
See PPFFCL at 67–68 ¶ 230. Still, even without UI
receiving all of Prince George’s “management infrastructure” from PeroxyChem’s Philadelphia
headquarters, Aetna, 240 F. Supp. 3d at 60; see Lerner Hrg. Tr. 1360:11–12, UI is likely to
replace PeroxyChem’s competitive intensity in the Pacific Northwest. See Montag Hrg. Tr.
1553:4–7; Kramer Hrg. Tr. 1627:11–17.
21
See FTC, The FTC’s Merger Remedies 2006–2012: A Report of the Bureaus of Competition
and Economics, at 1 (Jan. 2017), https://www.ftc.gov/reports/ftcs-merger-remedies-2006-2012-
report-bureaus-competition-economics (cleaned up).
36
PPFFCL
at 69 ¶¶ 233–35. The FTC argues that these provisions are red flags raising “serious and
substantial questions as to Prince George’s viability,” PPFFCL at 67 (cleaned up), but in fact,
these provisions show that UI is set up to compete into the future. 22
(D) UI’s Independence
Next, there is no reason to question whether UI will be an independent competitor in the
Pacific Northwest. The FTC challenges UI’s independence because it has ongoing commercial
relationships with Evonik and PeroxyChem as a customer for hydrogen peroxide, and UI leases
the land for its Mobile, Alabama, plant from Evonik. 23 PPFFCL at 70–71 ¶¶ 241–42. But
Cummins credibly dispelled this notion of undue influence. Cummins Hrg. Tr. 1742:5–1743:7.
The FTC also points out that when UI made its first offer to purchase the Prince George plant, it
PX1515-003. But that is just the nature
of selling a business, which is never completely seamless. UI may not—in fact, it will not—
secure every customer it pursues when it takes over the Prince George plant. But the record does
not cast doubt on UI’s ability to compete independently, given the protections in the divestiture
agreement, UI’s experience, and the scope of the divestiture. In fact, Prince George is likely to
be operating at capacity in 2020. See Cummins Hrg. Tr. 1753:5–21.
22
See also Decision and Order, In re Linde AG, FTC Docket No. C-4660 at 15 (Feb. 26, 2019),
https://www.ftc.gov/system/files/documents/cases/c4660_decision_and_ordermodified_
593725_public_redacted.pdf (showing similar non-solicitation provision in FTC consent decree
to protect divestiture buyer).
23
The FTC notes that Evonik can evict UI on short notice from this plant, PPFFCL at 70–71
¶ 242, implying that Evonik could do so to strongarm UI into coordinating on price or declining
to compete for certain customers. But there is no evidence in the record to suggest that the
Evonik-UI lease is not beneficial to both parties, and Evonik has denied all such intentions. See
Cummins Hrg. Tr. 1742:14–20.
37
(E) Purchase Price
Finally, the proposed purchase price does not cast doubt on the viability of the Prince
George plant if it is sold to UI. The FTC argues that the purchase price is cause for
concern because it is far lower than other third-party valuations of the plant. PPFFCL at 71
¶¶ 243–45. But there are a few explanations for the low price, none of which impact
Defendants’ showing that they will compete effectively in the Pacific Northwest.
First, to state the obvious, a potential buyer of an asset sold to facilitate a merger under
scrutiny by two countries’ antitrust authorities has enormous leverage over the seller because it
knows the seller must divest the asset quickly to proceed with the merger. DPFFCL at 52 ¶ 139.
This short timeframe puts UI’s rushed and minimal due diligence into perspective as well, see
PPFFCL at 66–67 ¶¶ 223–28. Although most companies contemplating such a purchase would
conduct more thorough diligence, the limited window for that diligence allowed UI to bargain
for a lower price. See id.; PX1515-002 to -003 (
). In short, by bidding the lowest price possible, UI acted like any rational actor in this
circumstance. Cummins Hrg. Tr. 1900:16–1901:10.
Second, that UI has no presence in the Pacific Northwest provided Evonik an even
stronger incentive to sell the Prince George plant to it, as opposed to a current hydrogen peroxide
supplier in the market like which valued the plant at . See PPFFCL at 71–
72 ¶ 246. It stands to reason that Evonik’s merger with PeroxyChem would be more likely to
survive antitrust scrutiny if it sold the Prince George plant to UI, since doing so would maintain
the same number of competitors in the Pacific Northwest.
The FTC suggests that the purchase price would allow UI to sell off the Prince
George plant for parts or drive it into the ground and still turn a profit. See PPFFCL at 71
38
¶¶ 243–45. To the contrary, the evidence shows that UI is a good-faith purchaser that intends to
compete effectively in the hydrogen peroxide market and grow the business, and it has strong
incentives to do so.24 See, e.g., Cummins Hrg. Tr. 1742:17–1743:7, 1771:16–1773:17. UI’s
purchase of another hydrogen peroxide plant in Turkey just last year, which it has maintained
over the last six months, speaks to this good faith. DPFFCL at 48 ¶ 127. The FTC also makes
much out of UI’s lack of specific plans for the Prince George plant, as if UI may decide to ignore
the plant’s existing operating procedures and fire its employees. See PPFFCL at 69 ¶ 236. That
seems highly doubtful. See DPFFCL at 50–51 ¶ 135. UI is buying a plant from PeroxyChem
with all of the key assets and day-to-day operations in place; there was no obvious reason at the
time of the evidentiary hearing for it to have developed its own specific plan.
Ultimately, “antitrust deals in ‘probabilities, not certainties.’” Aetna, 240 F. Supp. 3d at
60 (quoting Brown Shoe, 370 U.S. at 323). And Defendants’ burden is only to show that the
divestiture will likely replace PeroxyChem’s competitive significance in the Pacific Northwest.
Defendants have far exceeded that threshold. For these reasons, just as the Canadian
Competition Bureau found when approving the UI divestiture with respect to western Canada,
see Consent Agreement, ECF No. 141-1 at 10, 12–13,25 the Court finds that the merger is not
likely to “substantially . . . lessen competition” in the FTC’s proposed Pacific Northwest market.
24
UI’s good-faith desire to compete in the hydrogen peroxide industry is one of many features
that distinguish it from the failed divestiture in Aetna, 240 F. Supp. 3d at 72. See id. at 62, 72–73
(proposed divestiture buyer “repeatedly tried to enter” the market in the past and failed); id. at
63, 65 (buyer would not acquire anything resembling a standalone business); id. at 65 (buyer
showed substantial doubts about its own ability to succeed); id. at 72 (purchase price 1/10th of
fair market value).
25
But see ECF No. 142 at 3 n.2 (comparing standards for merger remedies in the United States
and Canada).
39
15 U.S.C. § 18. As a result, that proposed geographic market cannot assist the FTC in showing
its likelihood of success on the merits.
ii. Southern and Central United States
The FTC’s other proposed geographic market is the Southern and Central United States.
As already noted, the FTC bears the burden to define a relevant geographic market, Cardinal
Health, 12 F. Supp. 2d at 49, the region “in which the seller operates, and to which the purchaser
can practically turn for supplies.” Tampa Elec. Co. v. Nashville Coal Co., 365 U.S. 320, 327
(1961); see also Cardinal Health, 12 F. Supp. 2d at 49 (relevant geographic market is the area
“to which consumers can practically turn for alternative sources of the product and in which the
antitrust defendants face competition” (citation omitted)). As this definition suggests, a
geographic market is dependent on a properly defined product market—no court can assess “the
area of effective competition” for a product without defining the product itself. E. I. du Pont de
Nemours, 353 U.S. at 593 (quoting Standard Oil, 337 U.S. at 299 n.5); Tampa Elec., 365 U.S. at
328; see Merger Guidelines § 4.2 (“The [Government] applies the principles of [geographic]
market definition described here . . . to define a relevant market with a geographic dimension as
well as a product dimension.”); Merger Guidelines § 4.2.1 (“The hypothetical monopolist test
requires that a hypothetical profit-maximizing firm that was the only present or future producer
of the relevant product(s) located in the region would impose at least a SSNIP from at least one
location . . . .”) (emphases added).
Here, the Court has already explained that at least on the current record, the only relevant
product markets are hydrogen peroxide products formulated for specific end uses. But the FTC
argues that its proposed Southern and Central United States geographic market is the area of
competition for all non-electronics hydrogen peroxide because, in its view, customers for that
broader product market can choose from all five “freight-logical” hydrogen peroxide suppliers.
40
See PPFFCL at 21 ¶ 68; id. at 23 ¶ 74; id. at 26–27 ¶¶ 83–84, 87, 90, 93; id. at 28 ¶¶ 95, 99.
Accordingly, then, the FTC relied on evidence that suppliers of all manner of hydrogen peroxide
products bid and compete for customers across the purported “Southern and Central United
States.” See, e.g., PPFFCL at 23–25 ¶¶ 74–77. Dr. Rothman also conducted the hypothetical
monopolist test for “H2O2 sold to customers that are located in these states.” Id. ¶ 73. But none
of that evidence or analysis is tailored to a relevant geographic market for each relevant product
market—specific end uses of hydrogen peroxide. Because that evidence does not correspond to
the relevant product markets, it is of little use to the FTC in meeting its burden of showing an
undue concentration in a market for a particular product in a particular geographic area.
The FTC need look no further than its own challenge to the proposed merger in Sysco to
see what is missing here. In Sysco, the FTC defined relevant product markets based on customer
type: “broadline foodservice distribution” to local customers and “broadline foodservice
distribution to national customers.” 113 F. Supp. 3d at 48–49. For the national product, as the
name indicates, the FTC defined one relevant national geographic market. Id. at 49. But for the
local product, the FTC defined 32 relevant local geographic markets where the merging firms
have dominant market shares. Id. at 49, 52. Here, the FTC could have pleaded and argued a
Southern and Central United States geographic market for its proposed non-electronics product
market and also argued for alternative geographic markets corresponding to each end-use
product market. But it did not. So the Court is left with product markets disconnected from any
proposed geographic markets in which to analyze competition for those products.
To be sure, a geographical market need not be defined by precise metes and bounds.
Gen. Dynamics, 415 U.S. at 521. But the record contains substantial evidence suggesting that
the Southern and Central United States would not be the relevant area of effective competition
41
for each end-use hydrogen peroxide product. For pulp and paper customers, for instance,
because of the narrow profit margins, “it’d be cost prohibitive to ship hydrogen peroxide all the
way across the country,” Anderson Hrg. Tr. 199:23–25 (cleaned up), whereas customers for
specialty end uses like aseptic packaging or chemical synthesis may look to the entire United
States for their hydrogen peroxide supply. See Lerner Hrg. Tr. 1379:13–24, 1381:6–18 (“freight-
logical market for pulp and paper” much narrower than for “specialties,” where suppliers “have a
much greater ability to ship those specialties literally anywhere on the land surface”); Hill Rpt.,
JX0066-028 fig. 4 (over percent of standard grade hydrogen peroxide in North America
served by nearest plant); DPFFCL at 89 ¶ 239. Indeed, the parties agree that in some cases, “it is
appropriate to define geographic markets in the hydrogen peroxide industry . . . as narrowly as
individual customers.” DPFFCL at 38 ¶ 102; PFFCL at 21 ¶ 69. Or take the case of pre-
electronics grade hydrogen peroxide, an end use and therefore a relevant product market all its
own. MGC, a customer in Arizona with plants opening soon in Oregon and Texas, “buys on the
order of 99 percent of pre-electronics that’s sold,” Hill Hrg. Tr. 2080:22–23, which is shipped
from . See Hancock Decl.,
JX0001-001 to -002; DPFFCL at 13 ¶ 35. It is therefore highly unlikely that the relevant
geographic market for pre-electronics is just the Southern and Central United States.
These examples merely illustrate why the Court cannot assume that the Southern and
Central United States is a relevant geographic market, especially when the FTC has not pleaded
or proved geographic markets that correspond to the relevant product markets, as it must. See
Cardinal Health, 12 F. Supp. 2d at 49. The FTC’s failure to sufficiently define a relevant
geographic market is another reason it has not met its burden here. Id.
42
2. Market Concentration
Because the FTC has failed to show a relevant product market with a corresponding
relevant geographic market in which competition occurs, a discussion of the next step of its
prima facie case—showing undue concentration in that market—is anticlimactic. The FTC has
not met its burden under Baker Hughes to show undue concentration “in the market for a
particular product in a particular geographic area.” 908 F.2d at 982.
“Market concentration, or the lack thereof, is often measured by the Herfindahl–
Hirschman Index (HHI).”26 Heinz, 246 F.3d at 716. The FTC has not provided HHIs or other
measurements for Evonik and PeroxyChem’s combined market share in any alternative market
for a particular end use—the only relevant product markets with which to examine the merger’s
competitive effects. That failure is dispositive. The Court is unaware of a single case in which a
26
The HHI is calculated by squaring the market share of each firm in the market and
adding up these squares (so, if there are three firms with market shares of 50%,
30%, and 20%, the HHI would be 502 + 302 + 202 = 3,800). Squaring the
individual market shares allocates proportionately greater weight to firms with
larger shares, reflecting the larger threat to competitive behavior they
pose. See Merger Guidelines § 5.3. For antitrust purposes, the FTC and the U.S.
Department of Justice generally classify markets as “unconcentrated,”
“moderately concentrated,” and “highly concentrated.” An unconcentrated
market features an HHI of below 1,500. A moderately concentrated market has
an HHI of between 1,500 and 2,500, while a highly concentrated market has an
HHI that is greater than 2,500. Id.
Economists calculate the HHI score of an industry before and after the proposed
merger. Transactions that result in an HHI increase of fewer than 100 points “are
unlikely to have adverse competitive effects.” Id. In moderately concentrated
markets, a transaction that increases the HHI by more than 100 points “potentially
raise[s] significant competitive concerns and often warrant[s] scrutiny.” Id.
Mergers “resulting in highly concentrated markets that involve an increase in the
HHI of more than 200 points will be presumed to be likely to enhance market
power.” Id. This presumption of anticompetitive effects “may be rebutted by
persuasive evidence showing that the merger is unlikely to enhance market
power.” Id.
FTC v. Tronox Ltd., 332 F. Supp. 3d 187, 207 (D.D.C. 2018)
43
court has enjoined a merger, even at this preliminary stage, where the Government failed to show
undue concentration in a relevant market as its prima facie case requires, almost always through
an HHI or similar metric. Baker Hughes explicitly places that burden squarely on the FTC. 908
F.2d at 982; see United States v. Anthem, Inc., 855 F.3d 345, 349, 353 (D.C. Cir. 2017)
(government has the “burden to demonstrate a highly concentrated post-merger market”); Heinz,
246 F.3d at 715; United States v. H & R Block, Inc., 833 F. Supp. 2d 36, 84 n.35 (D.D.C. 2011)
(“The Court is not aware of any modern Section 7 case in which the court dispensed with the
requirement to define a relevant product market.”). And a party’s failure to make out a prima
facie case is generally considered a “fundamental defect” that dooms its case. See Rose v.
Mitchell, 443 U.S. 545, 574 (1979) (“declin[ing] to overlook” party’s failure to “make out a
prima facie case of discrimination” even where the opposing party conceded otherwise);
Williams v. Boorstin, 663 F.2d 109, 118 (D.C. Cir. 1980) (“holding . . . no prima facie case” and
reversing judgment finding a Title VII violation); Baker Hughes, 908 F.2d at 991 (“production-
burden-shifting” framework for “discrimination suits under [T]itle VII” “similar” to Baker
Hughes framework for Section 7).
The FTC argues that no matter how the product markets are sliced, “the merger would be
presumptively illegal in most, if not all, of such narrower markets.” Br. at 14. High
concentrations in the Southern and Central United States in the overall standard and non-
electronics grade markets suggest that it is possible the FTC could avail itself of that
presumption in some more narrowly defined market for a specific end-use product. See
Rothman Rpt., JX0075-052 to -053 & n.159; Rothman Rebuttal Rpt., PX7102-010. But those
concentrations do not necessarily mean that is likely, given the issues discussed above with
delineating relevant geographic markets that correspond to end-use product markets. At bottom,
44
the Court cannot rely on guesswork to get the FTC over the hump. “[A]ntitrust theory and
speculation cannot trump facts, and even Section 13(b) cases must be resolved on the basis of the
record evidence relating to the market and its probable future.” Arch Coal, 329 F. Supp. 2d at
116–17.
There are also practical reasons why the Court should not deem the FTC to have made
out its prima facie case on this record, without an HHI calculated for a relevant product and
geographic market that the Court has found viable. The rest of the Court’s analysis on the merits
runs the risk of devolving into speculation. For example, the “more compelling the prima facie
case, the more evidence the defendant must present to rebut it successfully.” See Baker Hughes,
908 F.2d at 991; Arch Coal, 329 F. Supp. 2d at 129 (“Certainly less of a showing is required
from defendants to rebut a less-than-compelling prima facie case.”). But if the Court has no
direct measure of the strength of the FTC’s prima facie case connected to the relevant market, it
cannot weigh whether the evidence offered by Defendants is enough to rebut that case. More
generally, evaluating the persuasiveness of the additional evidence offered by Defendants in
rebuttal, and by the FTC in support of its ultimate likelihood of success on the merits, becomes
all but impossible. Some of that evidence might be relevant (and to some degree) to competition
in that narrower relevant market, and some might not. The Court has little way of sorting all that
out, when the parties have not tailored their presentations to the relevant market. And, it bears
mentioning, even the “mere possibility” of a substantial lessening of competition is not enough
to show a violation of the Clayton Act. Heinz, 246 F.3d at 713 (citation omitted); see also
Staples I, 970 F. Supp. at 1072 (“It is not enough for the FTC to show merely that it has a ‘fair
and tenable chance’ of ultimate success on the merits.”).
45
All of this is not to say that in a subsequent administrative proceeding, the FTC could not
calculate HHIs connected to end-use-specific product markets and relevant geographic markets
to make out its prima facie case. But the Court cannot say on this record—devoid of
particularized data for those relevant markets—that there is a “reasonable probability” that
Evonik and PeroxyChem’s merger would produce an undue concentration in a relevant market. 27
Heinz, 246 F.3d at 713 (citation omitted). Accordingly, the FTC has not met its burden of
demonstrating a prima facie case.
B. Defendants’ Rebuttal Evidence and the FTC’s Additional Evidence of
Anticompetitive Harm
Nonetheless, to provide as complete a review of the record as possible in this unusual
circumstance, the Court will not stop there. The Supreme Court has stressed that courts must
judge “the probable anticompetitive effects of the merger” “functionally” and based on “a further
examination of the particular market—its structure, history and probable future.” Gen.
Dynamics, 415 U.S. at 498 (quoting Brown Shoe, 370 U.S. at 321–22 & n.38) (cleaned up). Of
course, in General Dynamics, the Court only conducted a further examination “of the particular
market” after the Government met its prima facie burden, id. at 497–98, and the Court has
concluded that the FTC has failed to meet that burden. But even assuming that the FTC had
made out a prima facie case on this record, the Court could not conclude that it has shown a
27
One judge has gone so far as to suggest that a plaintiff “may” prove a Section 7 violation even
without meeting its prima facie burden under Baker Hughes to “defin[e] a market and show[]
undue concentration in that market.” Whole Foods, 548 F.3d at 1036 (Brown, J.) (citing Baker
Hughes, 908 F.2d at 982–83; United States v. El Paso Natural Gas Co., 376 U.S. 651, 660
(1964)). Even if the FTC here could meet its prima facie burden without showing undue
concentration in a relevant market—instead relying on other evidence of anticompetitive harm
such as predicted price effects, e.g., Rothman Rpt., JX0075-094 & n.324, -097 to -099 & nn.334,
339, 344; id. -104 to -106 & nn.350, 354, 356, 358—that record evidence would not make out a
prima facie case for the reasons already described. The FTC’s threshold failure to define a
relevant market hamstrings its ability to show (and the Court’s ability to evaluate) a likely and
substantial lessening of competition.
46
likelihood of success based on Defendants’ rebuttal evidence and the FTC’s additional evidence
of anticompetitive harm.
In undertaking an evaluation of that evidence, the Court’s review is necessarily limited.
As explained above, much of this additional evidence—especially the dueling quantitative
models developed by Dr. Rothman and Dr. Hill—is grounded in the FTC’s proposed product and
geographic markets, which the Court has rejected. The Court cannot know much about what, if
anything, that evidence might mean for the effects of the proposed merger on different product
and geographic markets.28 The Court notes only that Dr. Hill, who has testified on behalf of the
FTC and against proposed mergers on several occasions, asserted based on his models that even
in the market as conceived by the FTC, the merger would not result in a substantial reduction of
competition. Dr. Rothman took the opposite view.
That said, other evidence applies to how the industry operates as a whole and is therefore
less dependent on the FTC’s proposed product and geographic market definitions. The Court
does its best to assess that evidence below. And after doing so, it concludes that the current
hydrogen peroxide industry is not particularly vulnerable to coordination, what vulnerability
exists is not likely to increase as a result of the merger, and the evidence does not show a
likelihood that the merger will cause substantial unilateral anticompetitive effects.
There is no science to weighing the factors at play in an antitrust analysis. Only an
examination of the real-world evidence—including ordinary course documents, bidding data, and
28
The FTC introduced data on predicted first order approximation effects and merger simulation
predicted price effects for an alternative standard grade hydrogen peroxide product market in the
Southern and Central United States and in alternative geographic markets in the Southern,
Central, and Western United States—none of which the FTC has shown are relevant markets.
See Rothman Rpt., JX0075-094 & n.324, -097 to -099 & nn.334, 339, 344; id. -104 to -106 &
nn.350, 354, 356, 358.
47
testimony from market participants—can supply an accurate picture of the industry and
competitive dynamics.29 That picture in this case reveals that hydrogen peroxide prices are
falling, and that competition is being promoted by blind bidding, sophisticated customers, and
the customary use of large and long-term contracts. The Court concludes that the proposed
merger is not likely to substantially change these market characteristics or substantially increase
prices.
1. The Market’s Vulnerability to Coordination
“Merger law rests upon the theory that, where rivals are few, firms will be able to
coordinate their behavior, either by overt collusion or implicit understanding, in order to restrict
output and achieve profits above competitive levels.” Heinz, 246 F.3d at 715 (internal quotations
omitted). Coordination is conduct by firms that is profitable for each of them only if the others
accommodate it. Merger Guidelines § 7. Tacit coordination, the FTC’s theory in this case, is
enforced not by an explicit agreement, but by the “detection and punishment of deviations.” Id.
Firms’ ability to coordinate “depends on the strength and predictability of rivals’ responses to a
price change or other competitive initiative.” Id. Tacit coordination itself is not illegal; it is
firms making “independent production decisions to maximize profits. But a core purpose of
29
The Court admitted over 1,300 exhibits en masse at the beginning of the two-week evidentiary
hearing. See Hrg. Tr. 155:20–157:5; Final Exhibit List, ECF No. 135-2; Joint Report on
Defendants’ Outstanding Objections, ECF No. 139-1. But the Court did not accord all that
evidence equal weight. When a party cited an exhibit in its proposed findings of fact and
conclusions of law without laying a foundation for it at the hearing, or where it cited the
deposition of a witness who did not testify at the hearing, the Court granted less weight to the
evidence (and sometimes no weight). See, e.g., PPFFCL at 77 ¶ 263 (citing JX0021). That
weight depended on several factors. See Minute Order of October 23, 2019 (denying
Defendants’ request to exclude certain categories of evidence because the Federal Rules of
Evidence do not apply to preliminary injunction hearings, but noting that the Court would accord
weight to evidence depending on the manner in which it was presented, whether a foundation for
it was laid, and whether the circumstances suggested its relevance and reliability).
48
antitrust law is to scrutinize mergers that may make it easier for firms to collectively reduce
output, and indeed, to prevent mergers that are likely to do so.” FTC v. Tronox Ltd., 332 F.
Supp. 3d 187, 208–09 (D.D.C. 2018); see Brooke Grp. Ltd. v. Brown & Williamson Tobacco
Corp., 509 U.S. 209, 227 (1993). The Merger Guidelines advise that even where a market
“shows signs of vulnerability to coordinated conduct,” before challenging a merger, the FTC
must also “have a credible basis on which to conclude that the merger may enhance that
vulnerability.” § 7.1.
The FTC is right that some features of the hydrogen peroxide industry typically suggest
vulnerability to coordination. There are few suppliers, only five in the FTC’s proposed product
and geographic market. And fewer suppliers usually means that suppliers anticipate “stronger
and faster” responses from their rivals, which diminishes the reward from attracting a
competitor’s customers. Merger Guidelines § 7.2; see Rothman Hrg. Tr. 750:20–21
(“maintaining discipline through deterrence is more straightforward when there are fewer
firms”). Elasticity of demand in the hydrogen peroxide market is also extremely low, regardless
of end use. PPFFCL at 32–33 ¶¶ 113–17. In other words, customers are unlikely to substitute
away from hydrogen peroxide to a different chemical if suppliers coordinate to increase prices by
a significant amount. Accordingly, the incentives for suppliers to coordinate are stronger.
But taken together, the remaining evidence rebuts the notion that the current hydrogen
peroxide market is vulnerable to coordination.
First, blind bidding for hydrogen peroxide customers produces substantial cost savings
for customers and “frustrate[s] coordination among producers.” Arch Coal, 329 F. Supp. 2d at
144; see DPFFCL at 53–54, 66–67 ¶¶ 143–46, 173. In general, the bidding process in the
industry works as follows: a customer publishes an RFP for a given location, specifying the
49
hydrogen peroxide product, volume, and contract duration sought; suppliers submit confidential
bids; and then the customer typically lets one or more of the bidders know how competitive their
bid is (without sharing specific prices) so that they will lower their bid price. See DPFFCL at 15
¶¶ 42, 44; id. at 66–67 ¶ 173. This pitting of suppliers against each other lowers prices, even
when there are only two competing suppliers, because suppliers generally do not know which
other suppliers have placed bids. See id. at 67 ¶ 175. In this market, without specific knowledge
of competing bids, suppliers are incentivized “to submit aggressive bids” because “cheating”—a
departure from coordinated higher prices—“would not be detected until well after the fact, if
ever, and any punishment would come well after the fact as well.” Arch Coal, 329 F. Supp. 2d at
145. Accordingly, the average price of standard grade hydrogen peroxide in the Southern and
Central United States, measured across all end uses, has decreased each of the last three years for
three of the five hydrogen peroxide suppliers, Hill Rpt., JX0066-098 fig. 45, and prices have
declined for much of the rest of the industry as well, id. -097 fig. 44; see also id. -099 fig. 46
(annual customer savings from bidding competition for Southern and Central United States
customers).
Second, the use of large and long-term contracts in the hydrogen peroxide industry
incentivizes firms to “deviate from the terms of coordination,” FTC v. CCC Holdings, 605 F.
Supp. 2d 26, 64 (D.D.C. 2009) (internal quotation omitted), “even if they expect strong
responses by rivals,” Merger Guidelines § 7.2, because the stakes are so high and there are fewer
“opportunities for firms to punish one another.” Hill Hrg. Tr. 2059:14–15; see Arch Coal, 329 F.
Supp. 2d at 145; DPFFCL at 69–70 ¶¶ 179–81. Customers for hydrogen peroxide are typically
50
large manufacturers who consume an enormous volume of hydrogen peroxide annually. 30
DPFFCL at 69 ¶ 180. Contracts for those customers come up for bidding at most once a year,
and usually every other or third year. Id. at 69–70 ¶ 181. If a supplier loses out on too many
contracts, it cannot just turn to a customer base outside North America or find other ways to
increase demand; total volume in the hydrogen peroxide industry has remained relatively
constant, so suppliers understand they are competing for a limited base of customers. See
PPFFCL at 32 ¶ 114. In this small and stagnant pond of customers, competition for the bigger
fish is fierce. It is unlikely that suppliers would coordinate and decline to cast their rod for the
chance to reel any one of them in. Indeed, the record shows that suppliers typically bid
aggressively for those big contracts, as the Court discusses below when evaluating suppliers’
recognition of their interdependence.
Third, even if suppliers did try to coordinate their bidding behavior to increase prices, the
hydrogen peroxide industry is marked by sophisticated and powerful customers that are well
equipped to defeat coordination. See Merger Guidelines § 8; Wilhelmsen, 341 F. Supp. 3d at 70;
CCC Holdings, 605 F. Supp. 2d at 64 (“A sophisticated customer base makes price coordination
more difficult.”). Many hydrogen peroxide customers have dedicated procurement personnel
who are experienced at conducting RFPs, minimizing costs, and leveraging competing bids to
secure the best contract terms. See DPFFCL at 70–71 ¶¶ 183–85.
30
The FTC notes that some pulp and paper customers award business on a mill-by-mill basis, so
those large-volume buyers do not “inherently impede coordinated conduct.” PPFFCL at 99 ¶ 80;
see id. at 78 ¶ 268. Although this may mitigate the effect of large and long-term contracts
somewhat, each of those mills are still purchasing high volumes of hydrogen peroxide, and
competition is progressively stronger for this “shrinking pie” of pulp and paper customers.
Rhilinger Hrg. Tr. 2414:18; see Hill Hrg. Tr. 2205:20–2206:4; JX0089-003 (almost 19 million
pounds of hydrogen peroxide volume for pulp and paper mill).
51
Fourth, while previous collusion in an industry can give rise to a presumption that a
market is vulnerable to coordination, that presumption does not hold if “competitive conditions
in the market have since changed significantly.” Merger Guidelines § 7.2. Here, competitive
conditions in the hydrogen peroxide industry have changed significantly since some suppliers
engaged in price fixing nearly 20 years ago. See PPFFCL at 42–43 ¶ 143; DPFFCL at 72 ¶ 188.
The FTC argues that because the industry products, plants, actors, and capacity are roughly the
same now, nothing has changed. PPFFCL at 43–44 ¶¶ 144–48. But the very features of the
industry that enabled suppliers to fix prices—public price announcements, swap agreements, and
meet-or-release clauses, see DPFFCL at 73 ¶¶ 190–92—are largely nonexistent now, and there is
no reason to think they are likely to return soon. 31
31
For example, the record reflects only one public price announcement since 2016. See
PX2055-004; PPFFCL at 44 ¶ 149; DPFFCL at 73 ¶ 190. The FTC argues that
attempted to raise prices in 2018, an allegation it first leveled after the hearing in its proposed
findings of fact, PPFFCL at 44 ¶ 149 (citing JX0054 ; PX3028-
001), and without questioning the relevant witnesses about it at the evidentiary hearing:
Even so, it appears the attempted price increase was only communicated
to customers, not to the public. See PX3028-001; Mahr Hrg. Tr. 2421:23–2422:3. In addition,
when suppliers fixed prices two decades ago, they frequently reached swap agreements with each
other. DPFFCL at 73 ¶ 191. A swap agreement occurs “when there’s a customer that’s
relatively distant from its supplier, and that supplier makes a deal with a closer supplier to
instead serve the customer on its behalf.” Hill Hrg. Tr. 2066:19–22. A swap agreement lessens
the incentive to compete for customers in the first place because both parties to the swap benefit
from a single customer. Id. 2065:22–2067:1. And finally, suppliers used to include meet-or-
release clauses in their customer contracts. DPFFCL at 73 ¶ 192. That clause allows a customer
under contract who is offered a better price elsewhere to tell its current supplier, “[m]atch that
price or I’m going to make the contract invalid and switch to the other supplier.” Id. 2065:18–
22. Meet-or-release clauses also lowered suppliers’ incentive to compete aggressively in the first
place, and they served as “an early warning system for detecting deviations” from coordination.
Id. 2065:23–2066:7.
52
There is mixed evidence in the record relating to other factors that courts consider to
evaluate industry vulnerability to coordination. But on balance, the Court concludes that
Defendants have the better argument in each case, or at least that the factor is essentially neutral.
One factor is market transparency, on which coordination depends. A market is more
vulnerable to coordination if (1) “the terms offered to customers are relatively transparent,”
(2) there is “[p]rice transparency,” or (3) there is “transparency regarding the identities of the
firms serving particular customers” (which can give rise to “customer or territorial allocation”).
Merger Guidelines § 7.2. Here, the terms offered to customers in blind bids are opaque; aside
from knowing the basic terms requested in an RFP, suppliers have little way of knowing what
their competitors are offering. See DPFFCL at 66–67 ¶ 173. Price is also mostly opaque.
Suppliers have information about general pricing trends in the industry and each other’s
production costs, but systematic attempts by suppliers to track each other’s prices have largely
failed. See DPFFCL at 66–68, 77–78 ¶¶ 173, 176–77, 201; PPFFCL at 36–38 ¶¶ 127–130, 132;
Corson Hrg. Tr. 658:8–11 (“I know that the pricing information, we, kind of, stopped even trying
to maintain that because there was never a consistency, nor is this information available.”
(cleaned up)). On the other hand, suppliers gain a general idea of the relationships that develop
between certain suppliers and certain customers from the bidding process and their conversations
with customers. PPFFCL at 36–38 ¶¶ 130–31, 133.
Another factor is product and pricing homogeneity; the more homogenous products and
prices are, the more vulnerable the market is to coordination. CCC Holdings, 605 F. Supp. 2d at
61. Although hydrogen peroxide products are relatively homogenous—within end uses, but not
between them—pricing is heterogeneous and unpredictable for each product, largely due to the
substantial role that freight plays into pricing decisions. See PPFFCL at 33–34 ¶¶ 118–20;
53
DPFFCL at 65 ¶ 170; Hill Rpt. JX0066-028 fig. 4; id. -098 fig. 45 (average standard grade price
varies from 23 cents to 37 cents); id. -097 n.254 (standard grade hydrogen peroxide “typically
has less variation in price within it than do other grades”). These variations in price make it
difficult for suppliers to predict how consumers will react to their pricing decisions, which would
facilitate coordination.
In addition, plants operating at capacity can sometimes suggest a reduced incentive to
compete for customers aggressively, because suppliers can only serve so many of them. See
PPFFCL at 39 ¶ 136; JX0032-086; PX2484-001; cf. DPFFCL at 55 ¶ 147 (Solvay undercut
suppliers on price in 2017 after they expanded capacity). And the evidence here shows that
hydrogen peroxide suppliers are operating their plants nearly at capacity. Even so, other features
of the market—a significant portion of contracts up for bidding every year, large volume
contracts, and the need to keep plants running at capacity due to the high fixed costs of running
them—should still incentivize competition. See DPFFCL at 71 ¶ 184. Indeed, for those reasons,
every bidding cycle is crucial for suppliers. See, e.g., id. at 70 ¶ 181; Corson Hrg. Tr. 652:14–19
(“[T]he large volumes that come up . . . at the end of the year . . . expose us to a lot of risk as we
plan our production; our terminals; our whole logistics network around those customers. So if
there is a change, it affects us dramatically.”).
Finally, a market is conducive to tacit coordination “where producers recognize their
‘shared economic interests and their interdependence with respect to price and output
decisions.’” Arch Coal, 329 F. Supp. 2d at 131 (quoting Brooke Group, 509 U.S. at 227)). The
FTC’s theory of such coordination presupposes suppliers with an acute awareness of each other’s
interdependence, withholding bids to avoid downward “price spirals” or retaliation from
competitors. PPFFCL at 38–42 ¶¶ 134–41. But the evidence in the record on this point is mixed
54
at best. In most cases when suppliers expressed concern about retaliation from competitors,
those same suppliers proceeded to ignore that risk and undercut their competitors on price
anyway, in large part due to the large and long-term contracts at stake. See, e.g., PX1027-008
(Evonik recognizing “Competitive Repercussions” of taking Suncor business from
PeroxyChem); PPFFCL at 67 ¶ 229 (Evonik successfully bid on Suncor anyway); JX0112
(supplier “bit off a little more than they expected . . . in retaliation for [Evonik] picking up . . .
additional business”); PX2339-001 (“It’s really critical that we push for whatever extra share we
can get at ”); PX1307; PX1440.
Moreover, in the few instances when suppliers appeared to withhold bids after
acknowledging the potential for retaliation, those decisions also reflected legitimate business
considerations: for example, the supplier did not believe the contract at issue was large or long
enough to justify offering a lower price, or the supplier recognized it was not likely to be
competitive due to its location and the high cost of transporting hydrogen peroxide. DPFFCL at
76 ¶ 198; see, e.g., Montag Hrg. Tr. 1569:2–1570:19; id. 1574:14–1576:5 (discussing PX2190-
001 and that PeroxyChem sought a long-term commitment to justify the investment necessary to
serve the customer); PX1074; PX2337-001; PX2501-001.
In summary, the evidence does not show that suppliers are coordinating in the hydrogen
peroxide market to keep prices artificially high. As Defendants argued, “a market in which the
prices are falling is one in which it’s very unlikely that coordination is happening among
suppliers. If they are [coordinating], they’re doing a terrible, terrible job of it.” Mahr Hrg. Tr.
2312:24–2313:2. Rather, despite the relatively few suppliers and low demand elasticity,
suppliers appear to bid aggressively to win large and long-term contracts from sophisticated
55
customers. While the “structure and dynamics of the . . . market may permit coordination,” in
this case they “do not make coordination likely.” Arch Coal, 329 F. Supp. 2d at 140.
2. The Proposed Merger’s Effect on Coordination
The Merger Guidelines advise that even where a market “shows signs of vulnerability to
coordinated conduct,” before challenging a merger, the FTC must also “have a credible basis on
which to conclude that the merger may enhance that vulnerability.” § 7.1. The proposed merger
of Evonik and PeroxyChem is unlikely to do so. None of the above-described features of the
industry currently inhibiting coordination in the hydrogen peroxide market are likely to change
post-merger. DPFFCL at 78 ¶ 203. In other words, there is no reason to suspect that suppliers
will not continue to participate in a blind bidding system for long-term and large contracts to win
the business of sophisticated buyers.
The biggest change the proposed merger would bring about is to reduce the number of
suppliers who own plants in the Southern and Central United States from five to four. PPFFCL
at 45 ¶ 151. That change relates directly to market concentration and the FTC’s prima facie case,
and the Merger Guidelines suggest that the FTC must have an independent basis to conclude that
a merger will increase the likelihood of coordination, apart from whatever evidence it offers to
show undue market concentration. See § 7.1. In any event, there is no reason to think that
reducing the number of hydrogen peroxide suppliers from five to four will likely lead to
coordination. As described above, the industry is not especially vulnerable to it, and the record
contains no evidence that suppliers are coordinating to raise prices or withhold supply in the
FTC’s other proposed geographic market of the Pacific Northwest, in which only three suppliers
operate.
The FTC also argues that Evonik, which has historically maintained a “price over
volume” strategy, will be a market leader post-merger that can more easily discipline
56
competitors. PPFFCL at 45–46 ¶ 154–57. Setting aside whether such market asymmetry in fact
increases the likelihood of coordination, see Hill Rpt., JX0066-110 to -111, the FTC’s argument
is speculative and inconsistent with the record. Evonik is already the market leader in the
Southern and Central United States, Rothman Rpt., JX0075-168, and so the scenario the FTC
anticipates should have already come to pass. In fact, the evidence suggests the opposite.
Evonik has consistently undercut other suppliers in the bidding process, see, e.g., PPFFCL at 67
¶ 229; JX0112. And market-wide prices are decreasing even with Evonik as the dominant
player, see Hill Rpt., JX0066-097 to -099.
Moreover, even if suppliers act contrary to that evidence and try to coordinate, Nouryon
remains positioned to disrupt that behavior. “[C]ollective market power is diminished by the
presence of other market participants with small market shares and little stake in the outcome
resulting from the coordinated conduct, if these firms can rapidly expand their sales in the
relevant market.” Merger Guidelines § 7.2. Nouryon is well situated to expand its hydrogen
peroxide sales in the event of a price increase because it (1) is “the smallest of all of the
competitors,” Radlinski Hrg. Tr. 538:15; (2) has won business from suppliers in the past,
; and (3) has over pounds of excess capacity at its
Columbus, Mississippi, plant with only an utilization rate, Radlinski Decl., JX0009-
002; Radlinski Hrg. Tr. 545:17–21; Hill Rpt. JX0066-109. 32
32
The FTC relies on a benign remark by Nouryon’s Paul Radlinski to argue that
PPFFCL at 54 ¶ 179. But Radlinski testified that
Nouryon—
Hrg. Tr. 545:22–546:16. ,
See id. 545:17–21
(
).
57
While “the risk that a merger will induce adverse coordinated effects may not be
susceptible to quantification or detailed proof,” the FTC must still “have a credible basis on
which to conclude that the merger may enhance that vulnerability.” Merger Guidelines § 7.1. It
does not come close to meeting that standard.
3. The Proposed Merger’s Unilateral Effects
The FTC has also failed to show that the proposed merger is likely to have substantial
unilateral effects. “A merger is likely to have unilateral anticompetitive effect if the acquiring
firm will have the incentive to raise prices or reduce quality after the acquisition, independent of
competitive responses from other firms.” H & R Block, 833 F. Supp. 2d at 81. In industries like
hydrogen peroxide where buyers negotiate with sellers and play sellers off each other,
“[a]nticompetitive unilateral effects . . . are likely in proportion to the frequency or probability
with which, prior to the merger, one of the merging sellers had been the runner-up when the
other won the business.” Merger Guidelines § 6.2. To be sure, the evidence suggests that
Evonik and PeroxyChem compete head-to-head for some hydrogen peroxide customers, for some
end uses. See PPFFCL at 49–50 ¶ 167. As a result, the loss of PeroxyChem as a competitor may
lead to a price increase for some customers. But the question for the Court is whether the
proposed merger, as a whole, is likely to “substantially . . . lessen competition.” 15 U.S.C. § 18.
The evidence does not show that to be so.
A quantitative analysis of the unilateral effects, like market concentration, is impossible
without data reflecting a properly defined relevant market, bounded by both product and
geography. The FTC’s expert, Dr. Rothman, offered two economic models to illuminate the
merger’s likely unilateral effects, the “GUPPI” and the “second-score procurement merger
simulation model,” Rothman Rpt., JX0075-088, -100, both of which rely on markets the Court
has rejected. The GUPPI model—which predicts “upward pricing pressure” or “the magnitude
58
of the changes in incentives to compete aggressively”—relies on market shares of those ill-
defined markets to measure customers’ preferences for Evonik or PeroxyChem. 33 Id. -089, -091.
Likewise, Dr. Rothman’s second-score procurement merger simulation model—which
“estimate[s] the likelihood that Evonik and PeroxyChem are the two-highest surplus bidders for
customers”—relies on (1) “market shares,” and (2) transaction data aggregated “for all . . . non-
electronics hydrogen peroxide, as well as for . . . standard grade hydrogen peroxide only”, id. -
102, both of which are based on the FTC’s ill-conceived product and geographic markets. The
model then predicts price increases for all non-electronics grade hydrogen peroxide—and for an
alternative standard grade hydrogen peroxide product market—in the Southern and Central
United States as well as in alternative geographic markets in the Southern, Central, and Western
United States. Id. -103 to -106 & nn.349–50, 354, 356, 358. The problem is that the FTC has
not shown that the model’s “inputs” or “outputs” are grounded in relevant product or geographic
markets. The Court cannot assume that suppliers compete just as closely in smaller product-
geography cross-sections of the market; in fact, in many situations, that is clearly not the case.
And for these reasons, there is no basis for the Court to assume that the total predicted effect of
the merger calculated by Dr. Rothman is merely the sum total of these smaller product-
geography cross-sections. Because the Court has found the FTC’s proposed product and
33
Even setting aside the GUPPI’s market-share input, the model is unreliable here because:
(1) the Merger Guidelines only recommend using the GUPPI to predict upward pricing pressure
for “differentiated products,” § 6.1, and the products here are homogenous within each relevant
product market (hydrogen peroxide formulated for a specific end use), see Hill Rpt., JX0066-084
to -085; (2) the GUPPI “assumes that customers have little or no bargaining power,” Rothman
Rpt., JX0075-088, which is not the case with hydrogen peroxide customers; and (3) accurate
GUPPI results “require[] precise information on pass-through behavior,” and Dr. Rothman
provides no evidence to support his .8 pass-through rate of cost to price, see Hill Rpt., JX0066-
086 to -089.
59
geographic markets wanting, Dr. Rothman’s models are of little use to the FTC in showing likely
unilateral effects of the merger.
The remaining qualitative evidence in the record, to the extent that it is instructive given
the lack of a properly defined market, suggests that the proposed merger is unlikely to cause
unilateral effects that substantially lessen competition. This is so in large part because in
general, Evonik and PeroxyChem are not close competitors. Evonik’s Mobile, Alabama plant
and PeroxyChem’s Bayport, Texas plant—their two facilities in the Southern and Central United
States—largely sell hydrogen peroxide intended for different end uses. Hill Rpt., JX0066-057;
see DPFFCL at 86–88 ¶¶ 230–35. For example, about percent of Evonik’s production at
Mobile is standard grade hydrogen peroxide sold to pulp and paper customers, while only about
percent of PeroxyChem’s Bayport production serves the pulp and paper industry, and that
number is shrinking. See DPFFCL at 85, 88 ¶ 229, 235. Evonik and PeroxyChem also have
different geographic focuses, largely because of the significant freight costs for the shipment of
hydrogen peroxide and the location of their plants over 450 miles apart. See id. at 88–90 ¶¶ 236–
41. The closest possible market competitors for Evonik’s Mobile plant are Nouryon’s plant in
Columbus, Mississippi, and Arkema’s plant in Memphis, Tennessee. Id. at 89 ¶ 240. The
closest possible competitor for PeroxyChem’s Bayport plant is Solvay’s in Deer Park, Texas,
fewer than 10 miles away. Id.
After Evonik and PeroxyChem merge, those three competitors are well positioned to
check Evonik during the bidding process. Executives for Nouryon, Arkema, and Solvay testified
that because of the blind bidding system and the sophistication of their customers, they compete
just as aggressively to win contracts no matter how many bidders are involved. See Radlinski
Hrg. Tr. 574:18–25; Myrick Hrg. Tr. 507:17–508:6; Suter Hrg. Tr. 439:7–17. Nouryon’s Paul
60
Radlinski, General Manager for Bleaching Chemicals in North America, Europe, and Asia, has
38 years of experience with Nouryon and its predecessor company. Hrg. Tr. 536:19–24. He
explained at the evidentiary hearing that suppliers do not know “whether it’s one, two or three or
four” suppliers bidding on a given customer. Id. 587:14–17. “So my assumption is it’s always
four when we go in to bid. And if it’s only one there, the customer’s not going to tell us, [w]ell,
you were the second of four bids. They’re going to say, [y]our bid was not the lowest bid. You
need to sharpen your pencils and bring us back a new offer.” Id. 587:17–21. “We don’t have
transparency,” so “it’s just as competitive with one other competitor as it is with three.” Id.
588:3, 588:9–11. Because blind bidding in the hydrogen peroxide is “all or nothing,” “to win the
business, you have to beat everybody,” whether it is one or three competitors. Id. 588:17, 589:6.
Finally, unlike many cases in which the FTC alleges that a proposed merger would be
anticompetitive, the record contains no evidence that Evonik intends to raise prices post-merger.
DPFFCL at 62–63 ¶¶ 162–63; cf., e.g., Tronox, 332 F. Supp. 3d at 208 (merging company
planned to “slow down” or “manag[e]” production so that “prices will rise”); Wilhelmsen, 341 F.
Supp. 3d at 63 (internal document noted that if merger closed, it would “increase our ability to
charge far better prices”). Of course, such a smoking gun is not necessary for the FTC to meet
its burden. But here, the evidence reflects a perfectly legitimate reason why Evonik and
PeroxyChem would want to merge that has nothing to do with raising prices: the businesses
complement each other. The Chairman of Resource Efficiency for Evonik, Claus Rettig,
credibly testified that the reason the proposed merger is attractive to Evonik is that it wants to
expand into the specialty grade hydrogen peroxide market on which PeroxyChem focuses. See
Rettig Hrg. Tr. 1047:13–17, 1053:1–9. Those specialty grade products “promise higher returns
in terms of profitability” and “are more stable in economic downturns” relative to pulp and paper
61
products, id. 1047:14–15, particularly given the number of newsprint customers that have gone
out of business. See Corson Hrg. Tr. 640:14–641:2, 651:18–21.
Lacking a smoking gun, the FTC fires away with a few squirt guns: (1) a poorly informed
third-party consultant’s report, based on transaction data only from , predicting a price
increase, JX0140; see PPFFCL at 47–48 ¶ 161; DPFFCL at 62–63 ¶ 163; (2) a 2019 Evonik
internal presentation with a demand curve reflecting that if Evonik chose to raise prices, its sales
quantity would decrease, JX0129-037 to -038; see PPFFCL at 46 ¶ 156; DPFFCL at 77 ¶ 200;
(3) emails exchanged between a competitor’s employees, shortly after Evonik and PeroxyChem
announced the proposed merger, expressing hope that the industry’s falling prices would finally
plateau;34 and (4) out-of-court declarations by customers reflecting “a truism of economics: a
decrease in the number of suppliers may lead to a decrease in the level of competition in the
market.” Arch Coal, 329 F. Supp. 2d at 146; see PPFFCL at 51 ¶ 170. But customers “do not, of
course, have the expertise to state what will happen in the [hydrogen peroxide] market, and none
have attempted to do so.” Arch Coal, 329 F. Supp. 2d at 146. These declarations are not enough
to outweigh the overall trends in the hydrogen peroxide market reflected in the record:
decreasing prices, aggressive competition for sophisticated customers with large and long-term
contracts, and substantial cost savings from blind bidding. See DPFFCL at 57–62 ¶¶ 150–61.35
34
Defendants objected to the admission of these two exhibits, PX3000 and PX3020, emails
exchanged by employees. See ECF No. 139-1. The Court overrules the objections and
admits them, but gives them little weight. Documents such as these appear highly speculative,
and because most of their authors did not testify, the Court has little basis to assess their
reliability. Indeed, the FTC did not even bother to ask —the only author who did
testify—about them. See DPFFCL at 62 n.378.
35
Defendants argue that efficiencies or “logistics savings” from their merger may reduce the
price of hydrogen peroxide or offset any predicted price increase, DPFFCL at 96–97 ¶ 258, but
those purported savings are unverifiable and did not weigh into the Court’s analysis. See
62
As with the FTC’s shortcomings in showing undue concentration in a relevant market,
the Court does not mean to suggest that in a later administrative proceeding, it would be
impossible for the FTC to show coordinated or unilateral effects, based on a properly defined
product and geographic market, that could call the merger into question. But it does not win the
day on the record here. “Section 7 involves probabilities, not . . . possibilities,” Baker
Hughes, 908 F.2d at 984, and on this record the Court cannot say it is probable that the merger
will substantially harm competition.
For all these reasons, the FTC has not met its burden of showing a likelihood of success
on the merits.
C. The Equities
The Federal Trade Commission Act provides for a preliminary injunction to block a
merger when “such action would be in the public interest,” after “weighing the equities and
considering the Commission’s likelihood of ultimate success.” 15 U.S.C. § 53(b); see Heinz,
246 F.3d at 726. “The primary public interest favoring preliminary injunctive relief in a Section
13(b) case, which Congress specifically contemplated, is the effective enforcement of the
antitrust laws. . . . Absent a likelihood of success on the merits, however, equities alone will not
justify an injunction.” Arch Coal, 329 F. Supp. 2d at 159.
The parties devote little discussion to the equities. They recognize that the propriety of a
preliminary injunction typically rises and falls with the FTC’s likelihood of success on the merits
and the public interest in enforcing antitrust laws. PPFFCL at 99–100 ¶ 81–82; DPFFCL at 100
¶ 269. Even so, the FTC argues that without a preliminary injunction, Defendants can
“‘scramble the eggs’—that is, combine their operations and make it difficult, if not impossible,
PPFFCL at 76–77 ¶¶ 260–61; Aetna, 240 F. Supp. 3d at 94 (“the estimate of the predicted saving
must be reasonable verifiable by an independent party”).
63
for competition to be restored to its previous state.” PPFFCL at 100 ¶ 82. For their part,
Defendants represent that if the Court grants the FTC a preliminary injunction, “the final closing
date will pass on February 3, 2020, and commercial imperatives will force the merging parties to
terminate their merger agreement.” DPFFCL at 16 ¶ 45; see Mahr Hrg. Tr. 2439:4–5. But there
is no need for the Court to resolve these competing equities. For all the reason explained above,
the FTC has not carried its burden of showing that it is likely that the proposed merger will
substantially lessen competition for a particular product in a particular geographic market. The
Court must therefore deny its request for a preliminary injunction.
Conclusion
For all of the above reasons, the Court will deny the FTC’s Motion for Preliminary
Injunction, ECF No. 3. A separate order will issue.
/s/ Timothy J. Kelly
TIMOTHY J. KELLY
United States District Judge
Date: January 24, 2020
64